ALL RIGHT. GOOD MORNING,
EVERYONE. WELCOME TO THE 6
FIFTH MEETING FOR BIOMEDICAL
IMAGINING AND BIOENGINEERING.
THIS COUNCIL MEETING IS OPEN TO
THE PUBLIC EXCEPT FOR REVIEW OF
PENDING GRANT APPLICATIONS THAT
TAKE PLACE LATER THIS AFTERNOON
AND OPEN SESSION OF THIS MEETING
IS LIVE BROADCAST ON THE NIH
NETWORK AND RECORDED FOR NIH
ARCHIVES AND COUNCIL MEMBERS IN
THE ROOM, WE ASK THAT YOU PLEASE
USE YOUR MICROPHONE WHEN YOU ARE
SPEAKING AND FOR EVERYONE IN THE
ROOM IF YOU TAKE A MOMENT TO
PLEASE MUTE YOUR PHONES.
I WILL FOLLOW MY OWN CRITIQUE
AND SHUT OFF SOUND FROM YOUR
LAPTOPS AND SO FORTH.
THERE WE GO. WE WELCOME COUNCIL
MEMBERS EX-OFFICIOS AND SPECIAL
GUESTS AND THANKS TO ALL WHO ARE
WATCHING ON VIDEO CAST.
MEMBERS OF THE PUBLIC WISHING TO
EXPRESS VIEWS REGARDING ITEMS
DISCUSSED IN THIS MEETING MAY DO
SO IN WRITING WITHIN THE NEXT 10
DAYS BY E-MAILING ME AT INFO AT
NIBIB.NIH.GOV. THAT IS
NIFO@NIDID.NIH.GOV.
PLEASE PUT NIV COUNCIL IN THE
SUBJECT LINE OF THE E-MAIL.
I WOULD LIKE TO NOTE FOR THE
RECORD WE HAVE A QUORUM FOR
TODAY'S MEETING AND THANK THE
OFFICER PAM GLITSSON ON THE ZOOM
TODAY NOT IN THE ROOM AND
MANAGEMENT ALICIA WHO IS IN THE
ROOM TODAY. THANK YOU FOR YOUR
HELP ORGANIZING THE MEETING AND
EXTRA EFFORTS TO SUCCESSFULLY
GET EVERYONE ON CAMPUS VERY
SMOOTHLY.
THANKS SO MUCH.
IR NEED TO NOTE THAT THESE
PROCEEDINGS ARE GOVERNED BY
FEDERAL ADVISORY COMMITTEE ACT
IN ADDITION OF THE GOVERNMENT
AND SUNSHINE ACT AND THAT MEANS
MEETINGS ANNOUNCED TO PUBLIC IN
FEDERAL REGISTER CONSISTS OF AN
OPEN PORTION TO THE PUBLIC WE
ARE IN, IN A MOMENT AND
DISCUSSIONS OF APPLICATIONS
LATER AND ANTICIPATE ADJOURNING
PUBLISH SESSION AT 12:30.
IN TERMS OF FUTURE COUNCIL DATES
TAKING A MOMENT TO DRAW
ATTENTION AT THE BOTTOM OF THE
AGENDA AND COUNCIL MEMBERS.
PLEASE DOUBLE CHECK THE DATES.
ON A DATE THAT MIGHT CONFLICT
WITH STUDENT COUNCIL MEMBERS AND
NEXT MEETING IS SEPTEMBER 10TH
2024 AND WILL BE AGAIN IN-PERSON
MEETING IN [INDISCERNIBLE]
CENTER AND FOES THOSE COUNCIL
MEMBERS WANTING TO BE COOL KIDS
ROBBING LITH 2. YOU ARE AMONG
THE COOL KIDS AND NOTING THAT WE
MENTIONED AT LAST COUNCIL WE
RESCHEDULED MAY OF 20205 COUNCIL
MEETING TO MAY 20TH SO IT
DOESN'T CLASH WITH THE ISMRM
MEETING AND COUNCIL MEMBERS AND
COLLEAGUES WILL ATTEND AS WELL.
WITH THAT I WOULD LIKE TO MOVE
CONSIDERATION OF THE MINUTES
FROM THE LAST COUNCIL MEETING
MADE AVAILABLE TO YOU A FEW
WEEKS AGO. ARE THERE ANY
COMMENTS OR MODIFICATIONS THAT
YOU WOULD LIKE TO MAKE TO THE
MINUTES?
HEARING NONE I WILL ENTERTAIN A
MOTION TO APPROVE.
IS THERE A SECOND? SECOND. ALL
IN FAVOR, AYE.
ALL OPPOSED, NAY.
THANK YOU. THERE IS NO
OPPOSITION AND MOTION PASSES AND
WITH THAT INTRODUCTION, I WILL
TURN THE PROCEEDING OVER TO DR.
TROMBERG.
>> OKAY. WE ARE BRINGING A
SLIDE UP AND THANK YOU, DAVID
FOR GETTING US STARTED AND GREAT
TO SEE YOU IN PERSON. WE LOOK
FORWARD TO MEETINGS TWICE A YEAR
IN PERSON.
IT IS AN ENERGY JOLT FOR ALL OF
US AND GOOD TO HAVE YOU HERE.
THIS IS A FAVORITE SITE. IT IS
THE HOME COURT OF TO DR. PLAT
WHO HAS LABORATORIES HERE AND
HOPE YOU GET TO SEE THE NEW LAB.
I'M VOLUNTEERING TOURS FOR YOU.
IT IS A BEAUTIFUL SPACE.
WE ARE PROUD OF MATRICES AND
WHAT YOU ARE DOING HERE. I
DON'T KNOW -- I THINK THIS IS A
6 FIFTH COUNCIL. IS THAT WHAT
YOU SAID, DAVE? I DON'T KNOW
HOW OFTEN NIBIB COUNCIL HAS BEEN
FLIPPED.
THIS IS AN INVERSE COUNCIL
MEETING AND NO DIRECTOR'S REPORT
IN THE MORNING. WE DID IT FOR
ONE SINGULAR REASON, TO HAVE OUR
SPEAKER, OUR SPECIAL COUNCIL
LECTURER THIS MORNING. WE ARE
PLEASED I AM PLEASED TO HAVE
SPEAKER DR. JANINE CLAYTON WHO
IS ASSOCIATE DIRECTOR FOR
RESEARCH ON WOMAN'S HEALTH AND
DIRECTOR FOR OFFICE OF RESEARCH
AND WOMEN'S HEAL THAJ IS SPECIAL
NIH INSIDE BASEBALL TERMINOLOGY
TWO TITLES FOR ONE SPECIFIC
LEADERSHIP ROLE. THAT IS
AWESOME. SHE IS CO-CHAIR FOR
NIH WORKING GROUP FOR WOMEN THAT
SHE CO-CHAIRS WITH DR. BER TAN
OELI AND ELECTED MEMBER OF BOARD
OF DIRECTORS TRIPLE AS AND A
LITTLE MORE I WILL GO ON FOR A
BIT MORE. I KNOW THAT JANINE
HAS SO MANY THINGS TODAY. SHE
WILL TELL YOU ABOUT THEM.
THAT IS WHY WE FLIPPED THIS.
SHE IS REALLY LEADING AN
INCREDIBLY EXCITING
INFORMATION-PACKED DAY THAT IS
ANNOUNCING MANY INITIATIVES YOU
WILL HEAR BEFORE THEY GO OUT
INTO THE PUBLIC.
SHE IS A BOARD-CERTIFIED
OPHTHALMOLOGIST AND RESEARCH IS
IN AUTO IMMUNE OCULAR DISEASES
AND ROLE OF SEX AND GENDER AND
HEALTH AND DISEASE AND HAS AN
AMAZING BACKGROUND AND VERY
STRONG INTEREST IN DISEASES
ASSOCIATED WITH PREMATURE
OVARIAN INSUFFICIENCY.
THIS WORK REALLY INSPIRED HER
UNDERSTANDING AND HER WORK ON
DESCRIBING HOW SEX AND GENDER
CAN INFLUENCE DISEASE AND HAS
LED TO THIS PIONEERING WORK WITH
DECLARATION OR UNDERSTANDING OF
SEX IS A BIOLOGICAL VARIABLE
ACROSS THE ENTIRE RESEARCH
SPECTRUM.
IT IS INSPIRED NOT ONLY WHAT IS
GOING ON IN OP THAMOLOGY ABOUT
YOU WHAT IS GOING ON IN
BIOMEDICAL RESEARCH ACROSS
BIOMEDICAL SPECTRUM AND RESEARCH
AUTHOR OF 120 SCIENTIFIC
PUBLICATIONS AND RESEARCH IS
SPANNING FROM RANDOMIZED
CLINICAL TRIALS IMMUNOTHERAPIES
TO MY FAVORITE DIGITAL IMAGING
INTERIOR SEGMENT OF THE EYE AND
IS SHE IS A FELLOWSHIP TRAINED
OPHTHALMOLOGIST AT WILL MER
INSTITUTE AT JOHNS HOPKINS DOING
WORK IN CORNEA AND INTERIOR
SEGMENT AND NEI HERE FOCUSING ON
IMMUNOOPHTHALMOLOGY AND
INTERESTING BACKGROUND.
SHE IS A NATIVE OF WASHINGTON,
DC WHICH WE SHARE.
WE HAVE BONDED A LOT OVER THAT
OVER THE YEARS.
AND SHE HAS RECEIVED SEVERAL
AWARDS INCLUDING THE AMERICAN
MEDICAL WOMEN'S ASSOCIATION LILA
WALLACE WOMEN'S HEALTH AWARD AND
WEN GER AWARD FOR EXCELLENCE IN
PUBLIC SERVICE AND BERN ADEAN
KEELEY AWARD IN WOMEN'S
LEADERSHIP AND -- OUTSTANDING
GOVERNMENT SERVICE AND SHE -- AS
I MENTIONED BEFORE SHE IS AN
ELECTED MEMBER OF AAA AND THIS
BOARD.
LET'S WELCOME DR. CLAYTON. WE
ARE SO PLEASED TO HAVE YOU HERE.
>> THANK YOU DR. TROMBERG FOR
THAT REALLY LOVELY INTRODUCTION.
IT IS NATIONAL WOMEN'S HEALTH
WEEK 2024. IT IS WHY THERE IS
SO MANY THINGS GOING ON TODAY.
YOU WILL HEAR MORE ABOUT THEM.
I'M REALLY HONORED TO BE HERE AT
NIBIB'S COUNCIL AND TALK TO YOU
A LITTLE ABOUT WOMEN'S HEALTH AT
THIS PARTICULAR TIME AND HAD TO
USE PHYSICS ANALOGIES FOR ALL OF
YOU.
IN TERMS OF FUL KRIM BEING IT IS
A MEANS TO GETTING SOMETHING
DONE AND THAT IS THE ANALOGY I'M
USING TODAY AS I SELECTED THIS
TITLE TECHNOLOGY AS A FULCRUM TO
MAXIMIZE TRAJECTORY OF WOMEN'S
HEALTH.
SO HOW TECHNOLOGY INNOVATION AND
HIGH-RETURN OPPORTUNITIES CAN
ADVANCE WOMEN'S HEALTH CARE IS
THIS STARTING POINT FOR MY TALK
HERE.
THERE ARE SO MANY WOMEN'S HEALTH
TOPICS AND AREAS OF NEED AND
ISSUES NEEDING TO BE ADDRESSED.
THOSE REPRESENT RESEARCH
OPPORTUNITIES FOR THE ENTIRE
BIOMEDICAL RESEARCH ENTERPRISE
AND IN PARTICULAR FOR THE
MISSION AREAS OF NIBIB.
I THINK WE ARE AT A TIPPING
POINT WE CAN REALLY ACCELERATE
PROGRESS BY APPLYING TECHNOLOGY,
ENGINEERING, IMAGING AND OTHER
ADVANCED STRATEGIES WHEN WE
CONVERGE ON THE HEALTH OF WOMEN
AND PUT ALL THAT SCIENCE AND
TECHNOLOGY TO WORK FOR THE
HEALTH OF WOMEN.
WE CAN DEVELOP WHAT WE CALL
SOLUTION STRATEGIES FOR THE
PROBLEM STATEMENTS WE ARE SO
FOND OF WRITING.
I TOOK A LOOK AT NIBIB'S MISSION
STATEMENT AND SAID THIS IS SO
WELL WITH NIH SEX AS A
BIOLOGICAL POLICY WHICH I WAS
REALLY PLEASED TO WORK ON WITH
MY COLLEAGUES HERE AT NIH.
FIRST IN TERMS OF PREVENTION, WE
KNOW THAT UNDER-REPRESENTED --
UNDERREPRESENTATION OF FEMALE
PARTICIPANTS IN NIH AND CLINICAL
RESEARCH OVER THE YEARS HAS LED
TO A LACK OF SEX-BASED ANALYSIS
OVER THE YEARS AND CREATED GAPS
IN OUR KNOWLEDGE AND,
UNFORTUNATELY, IT HAS LED TO THE
SITUATION WE HAVE THERAPEUTICS
THAT WERE NEVER TESTED IN
PARTICULAR IN WOMEN BEFORE
REVITALIZATION ACT AND
REVITALIZATION OF 1993 THAT WILL
REQUIRE THAT AND MEDICATIONS
WERE NOT TESTED IN WOMEN BUT MEN
AND FINDINGS WERE APPLIED MORE
BROADLY TO EVERYONE.
SOME OF THE MEDICATIONS HAVE
BEEN FOUND TO HAVE LOWER
EFFICACY IN WOMEN AND
UNFORTUNATELY GREATER TOXICITY
IN WOMEN.
IN TERMS OF TREATMENTS, WE KNOW
THAT SEX, A BIOLOGICAL VARIABLE
OF SEX WHETHER YOU ARE
SUSCEPTIBLE TO CERTAIN DISEASES
WE SEE DIFFERENCES IN PREVALENCE
OF DISEASE SEX AUTO IMMUNE
DISEASE 80% OF PATIENTS ARE
WOMEN AND WE SEE IT ALSO EFFECTS
YOUR EXPERIENCE OF DISEASE AND
YOUR RESPONSE TO TREATMENT AND
BENEATH THAT TREATMENT STATEMENT
IS ALL OF THAT UNDERLYING
FOUNDATION THAT WE NEED TO
CONSIDER.
IN TERMS OF TOOLS AND
TECHNOLOGIES THAT CAN HELP US
IDENTIFY PATHWAYS AND PROCESSES
TO IDENTIFY TARGETS CHARACTERIZE
HOW THE BODY FIGHTS DISEASE SUCH
AS THE IMMUNE SYSTEM AND
SAME-SEX DIFFERENCES IN THE
IMMUNE SYSTEM IF YOU DON'T KNOW
BEFORE COVID YOU SEE NOW AND SEE
HIGHER MORTALITY RATES IN MEN
VERSUS WOMEN AND PROCESS PAIN
AND LITERALLY DIFFERENT CELLS
ARE INVOLVED IN PAIN PROCESSING
AND MICROGLIA SEX AND HOW TO
MAINTAIN HEALTH PREVENTION AND
HEALTH PROMOTION AND IMPROVING
HUMAN HEALTH, WE USE MODELS OF
HUMAN DISEASE TO UNDERSTAND
HUMAN HEALTH AND IN SOME CASES
ANIMAL OR CELL-BASED MODELS ARE
USED TO INFORM UNDERSTANDING OF
HUMAN BIOLOGY AND DON'T
NECESSARILY RECAPITULATE WITH
FIDELITY IN TERMS WHAT WE SEE
WITH SEX DISEASES AND HUMAN
DISEASE AND HISTORICALLY WE
OVERRELIED ON MALE ANIMALS AND
MALE CELLS IN IN VITRO WORK.
HERE ARE SOME WAYS IN ADDITION
TO OUR EFFORTS TO PROMOTE
TRAINING WHERE WE HAVE DEVELOPED
ONLINE EDUCATIONAL RESOURCES
RELATED TO SIBIB AND HOW NIBIB
MISSION STATEMENT AND POLICY ARE
TRULY COMPLEMENTARY.
I WAS REAL EXCITED TO SEE YOU
LIKE WE ARE THINKING ABOUT A NEW
STRATEGIC PLAN AND GIVING A
SNEAK PEEK WE ARE RELEASING NEW
NIH-WIDE STRATEGIC PLAN ON
RESEARCH OF HEALTH AND WOMEN
TODAY. YOU ARE FIRST TO HEAR
IT. IT IS ONLINE NOW AND DR.
BER TAN OELI'S VIDEO TALKING
ABOUT HER VISION AND HOW NIH CAN
TURN DISCOVERY AND HEALTH FOR
EVERYONE IS AVAILABLE ONLINE NOW
AND NIBIB'S STRATEGIC PLAN IS
THINKING ABOUT FIVE AREAS AS YOU
GET INPUT. EACH AND EVERY ONE
OF THEM ARE HIGHLY RELEVANT TO
WOMEN'S HEALTH WHETHER ENGINEER
BIOLOGIC SYSTEMS THAT MIMIC
FEMALE REPRODUCTIVE TRACK OR
CENSORS AND CARE DIAGNOSTICS AND
FIRST WE COLLABORATED ON
MATERNAL HEALTH CHALLENGE AND
TRYING TO REALLY IDENTIFY, YOU
KNOW, EARLY SIGNS OF LABOR
PRETERM BIRTH DIAGNOSTICS
BIOMEDICAL ENGINEERING AND GOOD
FRIEND IS HERE AND A LOT OF THIS
WORK IS RELEVANT TO WOMEN'S
HEALTH AND LOTS OF WORK IS
INCLUDING WOMEN'S HEALTH RIGHT
NOW EVEN IF IT IS NOT CALLED
WOMEN'S HEALTH RESEARCH AND WANT
TO GIVE ALL THOSE TECHNOLOGISTS
AND IMAGEERS AND SCIENTISTS IN
THE AUDIENCE WORKING IN THAT
SPACE A SHOUTOUT AND PUT YOU TO
WOMEN'S HEALTH DATA SCIENCE
MODELING AND COMPUTATION IS
IMBEDDED IN NIH-WIDE STRATEGIC
PLAN AS ONE OF THE GOALS AND WE
ARE IN ALIGNMENT AND IN TERMS OF
ADVANCED THERAPEUTICS, WE KNOW
THAT WE ARE ON THE ROAD TO
PRECISION MEDICINE.
I WILL SAY ON THE ROAD.
WE ARE NOT THERE FOR EVERYTHING,
BUT WE HAVE MADE INCREDIBLE
ADVANCES BY IDENTIFYING
MOLECULAR TARGETS FOR LUNG
CANCER WE CAN INTERVENE ON.
LET ME PUT FORWARD TO YOU THAT
CONSIDERING SEX SHOULD BE THE
FIRST STEP ON THAT ROAD TO
PRECISION MEDICINE.
WE CAN'T REALLY BE PERSONALIZED.
WE CAN'T REALLY BE
INDIVIDUALIZED IF WE ARE NOT
CONSIDERING SEX AS A BIOLOGICAL
VARIABLE.
WE NOW KNOW THAT SEX OPERATES AT
EVERY LEVEL. GENE EXPRESSION
LEVEL, TISSUE LEVEL, ORGAN LEVEL
AND CERTAINLY AT ORGANISM LEVEL.
SO ADVANCED THERAPEUTICS, SIBIB
SHOULD BE PART OF THAT AND I'M
SURE IT WILL BE.
HOWEVER, WE DO KNOW THAT IF YOU
LOOK ACROSS THE HEALTH
ECOSYSTEM, WOMEN'S HEALTH IS NOT
THE FIRST THING WILL YOU SEE.
IF YOU LOOK AT WHERE INVESTMENTS
ARE GOING IN COMPLEX ECOSYSTEMS
AND MULTISECTOR ECOSYSTEM AND
INVESTMENTS IN WOMEN'S HEALTH
ARE NOT MOST ROBUST AS WELL.
HERE IS WHY THAT IS AN ISSUE AND
WHY I KNOW THAT EVERYONE IN THE
ROOM AND EVERYONE HEARING THIS
WILL DO SOMETHING DIFFERENT
GOING FORWARD AND GLOBALLY WOMEN
WITH DEMENTIA OUTNUMBER MEN WITH
DEMENTIA 169 AND 2000 WOMEN IN
THE UNITED STATES HAVE REPORTED
ADVERSE EFFECTS FROM IMPROVED
MEDICATION AND 2% MORE
FREQUENTLY THAN MEN.
SOME OF THEM HAVE INVOLVED FATAL
[INDISCERNIBLE].
WOMEN ARE UNDER-REPRESENTED AND
SURGICAL CLINICAL TRIALS FOR
SPECIFIC CANCERS OF THE BLADDER
HAD NEXT STOMACH AND ESOPHAGUS
AND CANCER CAN EFFECT WOMEN AND
MEN DIFFERENTLY AND SOME
COUNTRIES, SWITZERLAND AND WOMEN
PAID HIGHER INSURANCE PREMIUM
THEN MEN DO THAT LIMITS ACCESS
TO CARE AND THINK THIS AUDIENCE
IS AWARE THAT COMPENSATION AND
REMUNERATION FOR PHYSICIANS
PERFORMING PROCEDURES DIFFERS
FOR WOMEN AND MEN IF THEY ARE
SIMILAR PROCEDURES EVEN.
IN ADDITION, WE KNOW THAT THE
EFFECTIVENESS OF SOME
INTERVENTION IS LOWER FOR WOMEN.
THE ACCESS TO SOME INTERVENTIONS
IS LOWER.
54% OF INTERVENTION STUDIES WERE
FOUND TO PUT WOMEN AT A
DISADVANTAGE BECAUSE OF LOWER
EFFECTIVENESS AND LESS ACCESS OR
BOTH FROM MACKENZIE REPORT THAT
LOOKED ACROSS THE ENTIRE SECTOR
AND HERE IS DATA THAT IS
DEMONSTRATING THAT SINCE 1980,
[INDISCERNIBLE] 3.5 TIMES MORE
LIKELY TO BE REMOVED FROM THE
MARKET BECAUSE OF SAFETY RISKS
IN WOMEN COMPARED TO MEN AND
WANT TO ALSO ADRAW YOUR
ATTENTION TO THE GREY BAR THAT
IS WHERE IT WAS UNKNOWN HERE.
INSUFFICIENT DATA.
BECAUSE THE DATA WAS PROBABLY
NOT DISAGGREGATED BY SEX AND WE
REALLY DON'T KNOW AND NEED TO
REALLY KNOW THAT FOR EVERYONE'S
HEALTH.
IN TERMS OF THE ECONOMY, WE
SEE, I THINK, LARGE UNMET NEEDS
IN WOMEN'S HEALTH ARENA.
THOSE REPRESENT OPPORTUNITIES
AND TELLS GAPS IN MANY TOPICS.
I WILL HIGHLIGHT A FEW OF THEM
ENDOMETRIOSIS IN PARTICULAR THAT
IS A $200 MILLION MARKET IN THE
US UTERINE FIBROIDS HIGHLY
PREVALENT CAUSED [INDISCERNIBLE]
IN MEN AND WOMEN AND GREATER
PREVALENCE IN AFRICAN AMERICAN
WOMEN AND FURTHER RESEARCH
NEEDED AND MENOPAUSE THAT WILL
EFFECT EVERY FEMALE THAT LIVES
LONG ENOUGH TO EXPERIENCE IT
HIGH UNMET NEED AND ECONOMIC
[INDISCERNIBLE] THERE AND IN
TERMS OF DIGITAL HEALTH IS
STRATEGY ADDRESSING FERTILITY
AND INFERTILITY ISSUES SEEING
WITH START-UPS AND MENSTRUAL
PRODUCTS AND GYNECOLOGICAL
DEVICES AND GREAT OPPORTUNITY TO
ADDRESS THIS GENDER HEALTH GAP
AND IN TERMS OF ECONOMIC BENEFIT
WE KNOW THAT WOMEN PARTICIPATE
IN THE ECONOMY IN VARIETY OF
DIFFERENT WAYS IN ADDITION TO
AMAZING THINGS WE DO TOGETHER AS
COMMUNITY AND SOCIETY AND THEIR
PARTICIPATION IN THE WORKFORCE
IS A MAJOR DRIVER OF ECONOMIC
GROWTH OF COUNTRIES.
IF WE ADDRESS THE HEALTH GAP
THAT WOMEN FACE IT COULD REACH
THE GLOBAL ECONOMY BY ADDING 1
TRILLION WITH A T TO THE GLOBAL
ECONOMY BY 2040.
IF YOU DON'T AGREE WOMEN'S
HEALTH IS SOMETHING YOU SHOULD
PRIORITIZE, FROM AN ECONOMIC
PERSPECTIVE IT IS SOMETHING WE
ALL NEED TO CONSIDER MOVING
FORWARD.
GLOBAL GENDER HEALTH INNOVATION
GAP IS SOMETHING THAT ORWH IS
CONCERNED OF AS OF LATE AND
CO-AUTHORED THIS PIECE WITH
JAMIE WHITE TO BRING ATTENTION
TO GENDER HEALTH INNOVATION GAP
AND COLLABORATED WITH BILL AND
LINDA GATES FOUNDATION TO
CONVENE INNOVATION EQUITY FORUM
OR IES BRINGING TOGETHER 250 KEY
INTERESTED PERSONS FROM OVER 50
COUNTRIES WHO LOOK AT ONE OF THE
MOST CRITICAL WOMEN'S HEALTH R &
D GAPS.
SO WHY IS THIS AN INNOVATION
OPPORTUNITY?
WOMEN'S HEALTH OF COURSE
REPRESENTS AN UNTAPPED
OPPORTUNITY TO IMPROVE
WELLBEING.
TO PROMOTE MORE RESILIENT
HOUSEHOLDS AND COMMUNITIES AND
STRONGER ECONOMIES AND INCREASED
FINANCIAL DETOURENCE.
I THINK THAT IS THE CASE FOR
INNOVATION OPPORTUNITY.
WE CREATED INNOVATION
OPPORTUNITY MAP. HERE IS THE
INDIVIDUAL SECTORS WE INCLUDED
AND ENTIRE R & D ECOSYSTEM FROM
A GLOBAL PERSPECTIVE AND SEVERAL
CROSS-CUTTING TOPICS AND WILL
FLAG A FEW FOR YOU ONE SECTION
IS ON DATA AND MODELING AND ONE
ON INNOVATION INTRODUCTION AND
HERE IS THE US DATA.
IN THE US THERE IS 300 MILLION
DOLLAR INVESTMENT IN WOMEN'S
HEALTH RESEARCH COULD GENERATE
13 BILLION DOLLARS IN ECONOMIC
RETURNS AND THIS IS THE
FRAMEWORK FOR THE INNOVATION
OPPORTUNITY MAP.
WE LAID OUT 50 EQUITABLE
HIGH-RETURN OPPORTUNITIES TO
ADVANCE GLOBAL INNOVATION FOR
WOMEN'S HEALTH AND USED CRITERIA
AT THE TOP WHETHER POTENTIAL FOR
IMPACT AND WHETHER THEY ARE
READY FOR PROGRESS IN 5 TO 10
YEARS AND HAD TO BE INNOVATIVE
AND HAD TO MATTER TO WOMEN AND
WANTED IT TO BE WOMEN-CENTRIC
AND ADDRESS PROBLEMS WOMEN THINK
NEED TO BE ADDRESSED AND HAD TO
ADVANCE EQUITY. WE CALL THEM
PRIME CRITERIA AND FILTERED ALL
OF THE IDEAS AND SUGGESTIONS WE
GOT FROM INNOVATION EQUITY FORUM
FOR THE MONTHS ON THE CRITERIA
AND DRILLED THEM DOWN TO THE 10
MAJOR TOPIC AREAS.
UNDER EACH OF THE AREAS, THERE
ARE FIVE OR SIX SPECIFIC
OBJECTIVES AND OPPORTUNITY.
WHAT WE CONSIDER WOMEN'S HEALTH
FOR THIS IS ANYTHING THAT
EFFECTS WOMEN UNIQUELY. SO
FEMALE-SPECIFIC.
DIFFERENTLY LIKE AUTO IMMUNE
DISEASE OR DISPROPORTIONATELY.
I WANT TO JUST MAKE SURE YOU
UNDERSTAND THE UNIVERSE HERE IS
FAR BEYOND REPRODUCTIVE HEALTH
AND WE CONSIDER WOMEN'S HEALTH
EVERYTHING THAT EFFECTS WOMEN
FROM HEAD TO TOE INSIDE AND OUT
ACROSS THE ENTIRE LIFE COURSE.
SO AS A RESULT OF THAT
INNOVATION OPPORTUNITY MAP, WE
WOULD LIKE TO IMPLEMENT A
CROSS-SECTOR APPROACH TO ENGAGE
GLOBAL KEY INTERESTED PERSONS
PRIORITIZING WOMEN INCLUDING
VOICES OF WOMEN THEMSELVES AND
SOLVING PROBLEMS THAT WOMEN
BELIEVE NEED TO BE SOLVED
DEVELOPINO VATTIVE IDEAS AND
WORKING THROUGH STEPPING STONES
TO GET TO MILESTONES. WE KNOW
THIS IS A COMPLEX AND
CONSTRAINED ENVIRONMENT IN
PARTICULAR RIGHT NOW.
WHEN WOMEN'S HEALTH IMPROVES THE
HEALTH OF COMMUNITIES AND
SOCIETIES IMPROVE.
SO THIS IS A SMART INVESTMENT
FOR US ALL.
WHAT ARE WAYS WE ARE DOING THAT
THROUGH OUR PROGRAM AND OUR
SCORE PROGRAM IS SEX DIFFERENCES
CENTERS PROGRAM AND
[INDISCERNIBLE] PROGRAM IS
INSTITUTIONAL CAREER DEVELOPMENT
PROGRAM AND WE HAVE BOIRJ BIRCH
AND SCORE AND CREATING
TRANSLA
TRANSLATIONAL -- HERE THEY
INCORPORATE DIFFERENT NEEDS OF
WOMEN EXPLICITLY INTO THE WORLD
OF ENTREPRENEURSHIP AND PRODUCT
DEVELOPMENT TO PROMOTE
SCIENTIFIC DISCOVERY AND
OBJECTIVE IS TO FACILITATE
SEAMLESS TRANSITION FROM BASIC
RESEARCH TO CLINICAL APPLICATION
AND COMMERCIALIZATION AND
FOUNDATION OF THIS CONCEPT IS A
SCIENTIFIC WORK FLOW TOIN
EARTHIZE LABORATORY RESEARCH
INTO COMMERCIAL OUTPUT IN THE
FORM OF WORKFORCE AND WORK
PRODUCT THROUGH SEX DIFFERENCES
LENS AND WHAT IS THE DIFFERENCE
AND LOOKING AT EVERYTHING TO
[INDISCERNIBLE] LENS AND
LEVERAGING TWO PROGRAMS WE
SUPPORT ALONG WITH IC PARTNERS
AND TRYING TO DEVELOP A
DIAGNOSTIC ALGORITHM FOR SEX
SELECT IMMUNE MARKERS FOR
TARGETED TREATMENT AND TRYING TO
CREATE SEX SELECTIVE
NEUROMODULAR LATER PARAMETER
DEVICE THAT IS A PAIN AND THEY
ARE UTILIZING ULTRA IMAGING TO
EXPLORE SEX DIFFERENCES IN BLOOD
BRAIN BARRIER LEAKAGE FOR
TARGETING.
THAT WAS MY INTRO.
TELLING YOU ABOUT ORWH AND
EXCITED TO BE HERE AND TALK
ABOUT INNOVATION AND THINGS THAT
ARE IMPORTANT AND MISSION IS TO
EXPAND WOMEN'S HEALTH RESEARCH
AND WORK WITH ALL 27 INSTITUTES
AND CENTERS TO DO THAT AND
FOUNDED WHEN WOMEN WERE NOT
INCLUDED AT NIH BECAUSE OF
CONVENTION AND LACK OF
UNDERSTANDING THAT SEX OPERATES
AT A VERY BASIC LEVEL AND MOVE
FORWARD THERE AND
UNDER-REPRESENTED AND RACIAL AND
ETHNIC POPULATIONS AS WELL MUST
BE INCLUDED AND PROMOTE
ADVANCEMENT FOR WOMEN IN
CAREERS.
FIRST TIME ANYONE IS SEEING THAT
COVER AND NIBIB COUNCIL MEMBERS
AND ATTENDEES WE IMAGINE A WORLD
THAT SEX AND GENDER ARE
INTEGRATE AD CROSS ENTIRE
BIOMEDICAL RESEARCH SECTION FROM
IDEA TO THE LAB TO TRANSLATION
TO THE CLINIC TO THE APPLICATION
TO THE PUBLICATION TO INFORMING
NEXT HYPOTHESIS AND EXPERIMENT
TAILORED TO OWN CIRCUMSTANCES
GOALS AND NEEDS AND WORLD THAT
WOMEN AND SCIENCE MEET FULL
POTENTIAL AND CAN GET THEREIN
COLLUSION IS PART OF DNA AND WHY
WE WERE FOUNDED AND NIH
REHABILITATION ACT OF 1993 IN
THE UNITED STATES MUST BE
INCLUDED IN NI SUPPORTED
CLINICAL RESEARCH UNLESS
SCIENTIFIC REASON NOT TO DO SO
AND 21ST CENTURY MORE RECENTLY
TOOK THAT FURTHER AND NOW MUST
INCLUDE INDIVIDUALS OF ALL AGES
IN RESEARCH-R- -- SO WE CAN MAKE
TREATMENT DECISIONS TO TREAT
WHAT THEY HAVE AND DELIVER
EVIDENCE BASED CARE AND 21ST
CENTURY CARES ACT REQUIRES
TRIALS -- THAT IS A MAJOR
ADVANCE SO WE CAN SEE THOSE
RESULTS DISAGGREGATED IN.
BECAUSE WE KNOW INSIGHTS
GARNER + EXPANDED INCLUSION AND
ENHANCES ARIGOR AND ENHANCES
GENERALIZE NLT AND APPLICABILITY
OF THE STUDIES AND FINDINGS AND
BRUCE MENTIONING SEXING OF
BIOLOGICAL POLICY AND POLICY IN
A NUTSHELL AND EXPECT THAT SEX
AS A BIOLOGICAL VARIABLE WILL BE
FACTORED INTO RESEARCH DESIGN
ANALYSIS AND REPORTING
VERTEBRATE ANIMAL AND HUMAN
STUDIES AND EXPECT STRONG
JUSTIFICATION BE PROVIDED FOR
SINGLE SEX STUDIES THAT COULD BE
PERMITTED AND WE WANT STRONG
JUSTIFICATION AND JUSTIFICATION
THAT WE ALWAYS DO STUDIES IN
MALE ANIMAL MODEL ARE NOT
SUFFICIENT AND COLLABORATION IS
KEY TO EXECUTING AND
IMPLEMENTING NIH-WIDE STRATEGIC
PLAN AND WORK WITH INSTITUTES
AND CENTERS IN COORDINATING
COMMITTEE AND PARTNERSHIP AND
DRIVING SYNERGISTICALLY
PRIORITIES WORKING TOGETHER TO
DEVELOP PRIORITIES WORKING
GROUPS AND WORKSHOPS AND
PRIORITY SETTING AND WILL
ACHIEVE THE VISION I MENTIONED
FOR YOU AND WAY WE THINK ABOUT
THIS ACROSS THE LIFE COURSE AND
KNOW BIOLOGY MATTERS AND THAT WE
DON'T HAVE TO DEBATE WITH ANYONE
THAT HERE GENOME AND ANATOMY AND
IMMUNOLOGY MATTERS AND MYCOBIOME
MATTERS AND SOCIAL AND
ENVIRONMENTAL EXPOSURES MATTER
AND INTERACT WITH BIOLOGY ACROSS
THE LIFE COURSE AND THIS IS A
XREE HADDENCESIVE STRATEGY
THINKING ABOUT HEALTH OF WOMEN
AND ADDRESSING 1 OR 2 OF THESE
OR THESE SEPARATELY WE DON'T
HAVE SAME POWER IF WE INTEGRATE
AND WORK TOGETHER IN
INTERDISCIPLINARY MANNER TRYING
TO SOLVE SPECIFIC PROBLEMS WHERE
WE CONVERGE ON HEALTH OF WOMEN
AND APPROACH FOR GOING FORWARD.
I WAS REALLY HONORED TO BE IN
OVAL OFFICE WITH [INDISCERNIBLE]
AND SECRETARY BASERA PRESIDENT
AND FIRST LADY AND OTHERS
ANNOUNCING FIRST EVER WHITE
HOUSE INITIATIVE ON WOMEN'S
HEALTH AND RESEARCH WE SEE
WOMEN'S HEALTH RESEARCH NOT
WOMEN'S HEALTH BUT RESEARCH IS
BEING PRIORITIZED AT HIGHEST
LEVEL AND PRESIDENT AND FIRST
LADY ANNOUNCED THIS IN NOVEMBER.
PRESIDENT FOLLOWED UP WITH
SIGNING OF EXECUTIVE ORDER
EO14210 IN MARCH OF THIS YEAR
AND DELIGHTED TO BE THERE WAS
THE PRESIDENT AND FIRST LADY AND
VICE PRESIDENT AND SECOND
GENTLEMAN AND VARIETY OF LEADERS
YOU CAN SEE THERE FOR SIGNING OF
THIS HISTORIC EXECUTIVE ORDER
THAT IS AN AMAZING SET OF
STRATEGIES AND APPROACHES AND
DIRECTIVES THAT TALKS ABOUT
PRIORITIZING INVESTMENTS IN
WOMEN'S HEALTH RESEARCH IN
EVERYTHING WE DO INTEGRATING
WOMEN'S HEALTH RESEARCH ACROSS
THE FEDERAL RESEARCH PORTFOLIO
MAKING SURE WE GALVANIZES NEW
RESEARCH ON WOMEN'S MID-LIFE
HEALTH ASSESSING UNMET NEEDS TO
SUPPORT WOMEN'S HEALTH RESEARCH.
SOME OF THE STEPS WE ALREADY
HAVE COMMITTED TO TAKING HERE AT
NIH ARE SUMMARIZED ON THIS
SLIDE.
THE FIRST IS WE PREPARED WITH
EVERY SINGLE INSTITUTE AND
CENTER AND MULTIPLE OFFICES
NIH'S FIRST-EVER NOTICE OF
SPECIAL INTEREST ON WOMEN'S
HEALTH RESEARCH THAT IS LINKED
TO EVERY SINGLE NIH PARENT
FUNDING OPPORTUNITY AND WHAT IT
SAYS IS NIH IS INTERESTED IN
RECEIVING APPLICATIONS ON ALL OF
THE WORK THAT WE DO ACROSS ALL
OF THE FUNDING MECHANISMS ACROSS
ALL OF THE TOPICS AND ALL OF THE
DISCIPLINES.
THIS IS ESSENTIALLY A DEDICATED
FRONT DOOR FOR INVESTIGATORS TO
SEEK NIH FUNDING FOR WOMEN'S
HEALTH RESEARCH AND ARE WORKING
TO IDENTIFY AND DEVELOP NEW
COMMON DATA ELEMENTS RELATED TO
WOMEN'S HEALTH LIKE ON
MENOPAUSAL STATUS THAT WILL HELP
RESEARCHER SHARES AND COMBINE
DATA SETS AND WE WILL BE ABLE TO
PROMOTE INTEROPERABILITY OF DATA
SETS AND PROMOTE ACCURACY OF
DATA SETS PARTICULARLY AROUND
WOMEN AND ANNOUNCE INTENTION TO
INCREASE BY 50% NIH INVESTMENT
IN SBIR AND STT PROGRAMS RELATED
TO HEALTH OF WOMEN AND NEW
OPPORTUNITIES THERE.
WE ALSO ANNOUNCE LED BY OFFICE
OF DISEASE PREVENTION A PATHWAYS
TO PREVENTION PROGRAM ON
MENOPAUSE AND P TO P PROGRAM
THAT IS A ROBUST AND RIGOROUS
AND VERY PRESCRIPTIVE AND
WELL-RESPECTED PROCESS THAT
LOOKS CAREFULLY AT AN ISSUE
BEGINNING WITH SYSTEMATIC
EVIDENCE WORK WITH ARC AND
WORKSHOPS AND OTHER MEETINGS AND
WE ARE KICKING IT OFF TOMORROW
AT MENOPAUSE ROUNDTABLE AND
NATIONAL INSTITUTE OF CHILD'S
HEALLE AND HUMAN DEVELOPMENT LED
THE WAY ANNOUNCING NEW
INITIATIVE ON BIOMARKER
DISCOVERY AND PREVENT AND TREAT
CONDITIONS ON PROGRAM FOCUSED ON
ENDOMETRIOSIS AND THAT IS ON THE
STREET NOW AND LOOKING FORWARD
TO SEEING APPLICATIONS THERE AS
WELL AS OTHER PROGRAMS IN THE
CATEGORY AND A FEW OF THE THINGS
WE STARTED TO ADDRESS THIS
EXECUTIVE ORDER AND WANT TO MAKE
SURE YOU KNOW THIS EO EXTENDS
ACROSS US GOVERNMENT PARTNERS
OMB TO DOD TO BA TO EPA AND
USUAL COLLEAGUES IN HHS AND IN
CMS THEY ARE ALL PART OF THE
INTERDISCIPLINARY APPROACH AND
PRESIDENT ALSO IN STATE OF THE
UNION ADDRESS ACTS FOR 12
BILLION DOLLARS TO SUPPORT NIH
CENTRAL FUND ON WOMEN'S HEALTH
AND RESEARCH AND THAT IS A BROAD
ACT.
I MENTIONED SEX HAS EFFECTS AT
MULTIPLE LEVELS OF BIOLOGY AND
GENE TISSUE EXPRESSION STUDY, WE
KNOW THERE ARE MANY, MANY GENES
THAT ARE EXPRESSED DIFFERENTLY
IN MULTIPLE TISSUES IN THE BODY
AND WE KNOW THAT THE IMMUNE
SYSTEM AS ONE EXAMPLE DIFFER.
WOMEN HAVE A ROBUST RESPONSE TO
MICROORGANISMS GENERALLY THAN
MEN DO AND THAT ROBUST RESPONSE
TRANSLATES TO HIGHER RISKS FOR
AUTO IMMUNITY AND AT THE
ORGANISM OR PERSON LEVEL WE KNOW
WE SEE DIFFERENCES IN HOW
DISEASES SHOW UP AND HOW PEOPLE
RESPOND TO TREATMENTS ACROSS THE
LIFE COURSE AND WE NEED TO
INTEGRATE THAT INFORMATION
BECAUSE ALL OF THOSE LEVELS ARE
INTERACTING SIMULTANEOUSLY AND
WE ARE INTERACTING WITH THE
ENVIRONMENT AND WHETHER IT IS A
TOXIC EXPOSURE TO A TOX KANT OR
TAXIC RELATIONSHIP. ALL THAT IS
EFFECTING OUR HEALTH AND IT ALL
APPLIES TO CLINICAL CARE, WHICH
YOU KNOW.
IF WE COULD INTEGRATE ALL OF THE
DATA THAT WE ARE GATHERING
WHETHER EPIGENETIC DATA OR GENE
EXPRESSION DATA OR WHETHER
TRANSCRIPTOMICS, IF WE COULD
INTEGRATE ALL THAT INFORMATION
TO A SEX-DIFFERENCES LENS, NOW
THAT WE KNOW THERE ARE SEX
DIFFERENCES IN EPIGENETICS AND
SEX DIFFERENCES IN PROTEINS AND
LOOKING AT IT THROUGH
ENVIRONMENTAL INFLUENCES AGE AND
SEX ACROSS LIFETIME AND LIVE
COURSE PERSPECTIVE AND
COMORBIDITY THINK WHAT WE COULD
LEARN INSIGHTS WE COULD GARNER
ARE ENUMERABLE AND WE ARE
APPROACHING COMPUTATIONAL POWER
AND ADVANCED ANALYTICS
APPROACHES TO DO JUST THAT AND I
CALL ON INVESTIGATORS TO THINK
ABOUT WOMEN'S HEALTH WHEN THEY
ARE DOING THAT AND DESIGNING
ALGORITHMS AND ANALYTIC
APPROACHES AND WILL GIVE AN
EXAMPLE OF A PRESENTATION AT OUR
ADVISORY COMMITTEE JUST LAST
MONTH.
ROBERTA DIAZ WORKS IN COGNITION
AND ALZHEIMER'S IS PRIMARY AREA
OF FOCUS DOING RETROSPECTIVE
ANALYSIS AND DON'T HAVE TO DO
THAT. SUMMARIZING QUICKLY FOR
YOU AND RED DOT AND TO THE LEFT
OF IT AND LOOKING AT 400,000
INDIVIDUALS RECEIVING MENOPAUSAL
THERAPY AND WAS INTERESTED IN
NEURODEGENERATIVE DISEASE FROM
ALZHEIMERS TO PARKINSON'S TO ALS
AND [INDISCERNIBLE] IN ALL WOMEN
AND SHE DECIDED TO FOCUS ON ER
BETA AND DEVELOP PHYTOEST
TROEJEN MADE WITH COMPOUNDS THAT
ARE ALREADY SAFE WITH THE FDA.
THIS IS SELECTIVE FOR THE BRAIN
AND DOES NOT HAVE ACTIVITY IN
REPRODUCTIVE TISSUES.
HAS NOW MULTIPLE RO1S FROM THE
AGING INSTITUTE DOING A PHASE 2
CLINICAL TRIAL AND PROOF OF
CONCEPT FOR THIS PARTICULAR ER
BETA AGONIST TO DECLINE TO
ADDRESS DELINE IN BRAIN
METABOLISM AND COGNITION IN
MENOPAUSAL TRANSITION AND SBR
GRANT SHE HAS AND HIGHLIGHTING
HOW TO BRING ALL THESE TOGETHER
AND SHE IS ALSO LOOKING AT
MENOPAUSAL HOT FLASHES ALL THE
TIME.
I WANTED TO HIGHLIGHT THESE AS
AN EXAMPLE OF WAYS WE CAN BRING
THIS ALL TOGETHER.
TO PUT SCIENCE TO WORK FOR THE
HEALTH OF WOMEN THAT IS OUR
TIMELINE.
IF WE ACCOUNT FOR SEX AT
MULTIPLE LEVELS WHERE IT
OPERATES, WE CAN PROVIDE NEW
DIMENSIONS TO DATA AND GENERATE
NEW [INDISCERNIBLE].
WHEN WE LEVERAGE THOSE LARGE
DATA SETS CUTTING EDGE SCIENCE
AND ANALYTIC TOOLS WE CAN SOLVE
WOMEN'S HEALTH PROBLEMS
CONSIDERING HEALTH OF WOMEN IN
CLINICAL TRIALS WHEN DESIGNING
THEM UP FRONT MAKING SURE
INCLUSION CRITERIA ARE NOT
BIASED AND MAKING SURE OUTCOME
MEASURES WE SELECT ARE
APPROPRIATE FOR MEN AND WOMEN WE
CAN LEAD TO NEW TARGETS TO
BETTER [INDISCERNIBLE] NEW
TARGETS AND A GREATER
UNDERSTANDING OF SEX-SPECIFIC
EFFECTS.
OUR GOAL IS TO CLOSE THE GAP IN
WOMEN'S TECHNOLOGY BY APPLYING
TECHNOLOGY ADVANCED ANALYTICS
ENGINEERING IMAGING AND ANY
OTHER TOOL OR STRATEGY WE CAN
USE TO IMPROVE THE HEALTH OF
WOMEN AND WE DO IT THROUGH OUR
SIGNATURE PROGRAMS AND MENTIONED
SEVERAL ALREADY.
I WILL BRIEFLY MENTION MORE
RECENT PROGRAMS THAT IS NIH'S
FIRST-EVER RO1 AND LOOKING AT
INTERSECTION OF SEX AND GENDER
TOGETHER ON HEALTH AND DISEASE
AND PARTNERING 11IOCS ON THAT
AND FIRST EVERY R021 AND CHRONIC
DISEASES AND WOMEN LIKELY TO BE
EFFECTED BY CHRONIC DISEASE AND
WOMEN LIVE LONGER THAN MEN DO
AND MORE YEARS IN POOR HEALTH
NOT JUST IMPORTANT TO LOOK AT
LIFESPAN BUT HEALTH SPAN AND
NEED TO ADDRESS THOSE 8 YEARS ON
AVERAGE THAT WOMEN LIVE WITH
POOR HEALTH AND TECHNOLOGIES
WILL BE A WAY TO DO THAT AND
CITING HERE NATIONAL INSTITUTE
OF ENVIRONMENTAL HEALTH SCIENCES
INTRAMURAL PROGRAM BASIC AI
MACHINE LEARNING APPROACHES
LOOKING AT BODY OF WORK AND
MULTIPLE STUDIES THAT HAVE BEEN
PUBLISHED AND ARE TRYING TO
DIAGNOSE POLYCYSTIC OVARY SYSTEM
MOST COMMONLY DIAGNOSED SYSTEM
FOR WOMEN AND APPROACHED WITH
SYSTEM -- WOMEN ARE DELAYED AND
GET STREEMENT LATER AND AI AND
ML THIS APPROACH IS BASIC AND
WAS ABLE TO SUCCESSFULLY
DIAGNOSE PTOS FROM THIS LARGE
SET OF DATA THAT IS GENERATED
FROM MULTIPLE STUDIES IS
SOMETHING RELEVANT AND AVAILABLE
YOU CAN PUT WHAT TECHNOLOGY AND
TOOLS YOU HAVE AVAILABLE TO WORK
FOR THAT AND SMALL BUSINESS AND
EDUCATION AND ENTREPRENEURIAL
DEVELOPMENT PROGRAM IS A WAY
FUNDING CAN BE SECURED AND CORE
BUSINESS OBJECTIVES ARE LISTED
HERE AND THEY ARE LOOKING FOR
IMPACTFUL HEALTHCARE SOLUTIONS
SUPPORTING EARLY STAGE PRODUCT
DEVELOPMENTS FOR FUNDS AND
DIVERSE WORKFORCE AND IMPROVING
PATIENT CARE DRIVING ECONOMIC
GROWTH AND FUNDING OPPORTUNITIES
ARE LISTED HERE AND NOTICE OF
INFORMATION JUST WENT OUT
ANNOUNCING NIH'S INTENTION TO
PUT OUT NEW FUNDING
OPPORTUNITIES FOR SBIR AND TTR
AND HERE ARE ALL PARTICIPATING
ICOS AND NIBIB AND MENTIONED NEW
NO SEE NIH-WIDE RESEARCH LINKED
TO STT PARENT FUNDING
OPPORTUNITY AND THIS PROGRAM HAS
BEEN SUCCESSFUL ADVANCING
WOMEN'S HEALTH RESEARCH WITH
COMPANIES THAT I MENTIONED HERE
AND THEN ON THE RIGHT, THIS IS
AMERICA'S FUND THAT IS A ROAD
TOUR.
THEY ARE MOVING ACROSS THE
COUNTRY LITERALLY EVERY STATE BY
BUS OR TRAIN TO TALK ABOUT THIS
PROGRAM AND THE FOUR BILLION
DOLLARS IN FEDERAL FUNDS
AVAILABLE FOR EARLY STAGE
FUNDING OPPORTUNITIES SO PLEASE
CHECK IT OUT.
I MENTION GENE EXPRESSION BEING
DIFFERENT BY SEX AND HERE IS
DATA FROM COMMON FUND PROGRAM.
THIS IS SBIB IN ACTION AND
LOOKING AT MEN AND WOMEN 44
TISSUES ACROSS THE BODY COLOR
COATED WITH HISTOGRAM IN THE
MIDDLE AND FOUND 37% OF ALL
GENES EXHIBIT SEX BIASED
EXPRESSION AND LEAVES ONE TISSUE
AND I'M PRETTY SURE THERE IS A
CONSEQUENCE OF THAT GENE
EXPRESSION DIFFERENCE THAT YOU
CAN SEE HERE ON THE RIGHT THINGS
THAT YOU MIGHT RECOGNIZE PATTERN
BALDNESS HERE IN A BLUE DOT
MENTIONING SEX FOR MEN AND
[INDISCERNIBLE] I'M NOT SURE
WHAT YOU WOULD THINK OF THAT
PARAMETER AND JUST EVIDENCE OF
THE DIFFERENCES WE SEE AT MOST
BASIC LEVEL AND IN ANIMAL MODELS
ANIMAL MODELS MODELING HUMAN
DISEASE WE HAVE TO CONSIDER THIS
AS WELL AND WE KNOW THAT NO ONE
ANIMAL MODEL CAN RECAPITULATE
PATH OF FINDINGS YOU SEE IN
HUMAN DISEASE AND BIOLOGY GIVES
US NEW KNOWLEDGE TO EXPERIMENTS
AND STUDIES AND GENERATING
EXPERIMENTAL DATA AND USE
TECHNOLOGY FOR THAT AND
COMPUTATIONAL APPROACHES HELP US
GET NEW INSIGHTS THROUGH THIS
ENTIRE LIFE CYCLE WE DEVELOP NEW
UNDERSTANDINGS TO HEALTH OF
WOMEN AND BIOMEDICAL
TECHNOLOGIES BROADLY WHETHER
GENE EDITING OR AI OR USING
INDUCED PLURIPOTENT STEM CELLS
OR MICROANALYTICS IS WAYS TO PUT
SCIENCE TO WORK FOR HEALTH OF
WOMEN AND TO DIRECTOR RECENTLY
HAD [INDISCERNIBLE] PERFORMED ON
NOVEL ALTERNATIVE METHODS MOVING
BEYOND ANIMAL STUDIES GETTING
NEW INSIGHTS AND HERE
HIGHLIGHTED ON RIGHT POWER OF
INTEGRATED NOVEL ALTERNATIVES
METHODS ECOSYSTEM AND TRAINING
ON THAT MULTI-DISCIPLINARY TEAMS
ADDRESSING PARTIAL
RESPONSIBILITY AND COORDINATED
INFRASTRUCTURE AND INCREDIBLE
POTENTIAL HERE TO INCLUDE SEX AS
A BIOLOGICAL VARIABLE AND ONE
WAY THAT BIB HAS DONE IN PAST IS
THROUGH IMAGING RESEARCH AND
HIGHLIGHTING ONE EXAMPLE AND
SUPPORT FOR CARDIAC MRI IMAGING
AND IMAGING TECHNIQUES HAVE BEEN
HIGHLY RELEVANT TO WOMEN'S
HEALTH AND WOMEN TEND TO HAVE
N
NONOBSTRUCTIVE CORONARY PATTERN
NOT PICKED UP ON GOLD DIAGNOSTIC
STANDARD TEST THAT IS CORONARY
ANGIOGRAM AND WHY WOMEN WILL
PRESENT IN EMERGENCY ROOM AND
HAVE NORMAL CARDIO ANGIO GRAM
AND BE HAVING A HEART ATTACK AND
BE SENT HOME AND CHOLESTEROL
PLAQUE PATTERNS ARE DIFFERENT
AND CORONARY REMODELING AND
[INDISCERNIBLE] IS DIFFERENT AND
I WILL HIGHLIGHT THAT MICRO
VASCULAR DISEASE IS MORE COMMON
IN WOMEN THAN MEN AND MICRO
VASCULAR DISEASE IS NOT
NECESSARILY ALWAYS DETECTED BY
OUR GOLD STANDARD TEST BUT
CARDIAC MRI AND IMAGING
TECHNIQUES ARE SALIENT TO
DIAGNOSING [INDISCERNIBLE] AND
SEX AND GENDER IS ON OUR
NATIONAL RADAR. IT IS ALSO ON
THE INTERNATIONAL STAGE AS WELL.
THE WORLD HEALTH ORGANIZATION
RECENTLY ADOPTED SEX AND GENDER
EQUITY AND RESEARCH GUIDELINE
DEVELOPED TO PROMOTE SEX AND
GENDER EQUITY AND RESEARCH
ESPECIALLY AROUND PUBLICATION
AND JOURNALS AND PUBLISHERS
ADOPTED THE GUIDELINE AND I WAS
EXCITED TO BE ON A PANEL WHEN
WHO ANNOUNCED THAT ALONG WITH
THE CREATOR OF THE GUIDELINES.
WE HAVE RECENTLY A WEBINAR WHERE
WE TALKED ABOUT SIBIB AND SEX
AND RESEARCH AND I WAS REALLY
EXCITE TODAY BE AT PRECISION
MEDICINE WORLD CONFERENCE ON THE
STAGE RECEIVING AN AWARD WHERE
THEY TALKED ABOUT HOW ALL OF
PRECISION MEDICINE NEEDS TO
CONSIDER HEALTH OF WOMEN EARLIER
THIS YEAR AND WITH SOMETHING
ABOUT CAREERS AND HERE IS DATA
AND OVER TIME THE NUMBER OF
SUPPORTIVE PIS ON RESEARCH
PROJECT GRANTS BY SEX AND FISCAL
YEAR IN ORANGE AND MALES AND
GREY FEMALES AND SEE NO SLIGHT
UPTICK OR REAL CHANGE IN BLUE
THAT IS NOT REPORTED AND WE KNOW
THAT WOMEN AND MEN ARE EQUALLY
LIKELY TO BE FUNDED WHEN THEY
APPLY.
THAT HAS BEEN SHOWN MULTIPLE
TIMES FOR NIH GRANTS AND WOMEN
TEND TO NOT COME BACK IN FOR
SECOND RPGS AND WE ARE NOT
REALLY SEEING ANY MOVEMENTS
SUBSTANTIAL MOVEMENT ON THIS AND
NUMBERS OF WOMEN SEEKING
COMPUTER SCIENCE MAJORS WAS
GOING UP AND NOW IS GOING DOWN
AND WE CLEARLY HAVE WORK TO DO
IN THIS SPACE OF WHO IS IN THE
RESEARCH WORKFORCE AND WHOSE
IDEAS ARE WE CONSIDERING AND HOW
CAN WE GET ALL OF THE BRILLIANT
MINDS IN SCIENCE SO WE CAN
[INDISCERNIBLE].
SO INSTEAD OF A PIPELINE WE ARE
TALKING ABOUT A BRAIDED RIVER
FOR ANALOGY FOR CAREERS TODAY
AND WE WANT INDIVIDUALS TO COME
INTO THIS FROM MULTIPLE ENTRIES
AND EXITS AND WANT THEM TO COME
FROM COMMUNITY COLLEGES AND WANT
THEM TO BE ABLE TO MOVE ACROSS
CREEKS AND ETES AND STREAMS HERE
TO MOVE FROM ONE SECTOR TO
ANOTHER AND LEAVE SCIENCE THAT
THEY NEED TO HAVE CAREGIVING
RESPONSIBILITIES AND HAVE A RAMP
TO GET BACK ON AND KNOW IF
INDIVIDUALS HAVE EXPERIENCES IN
MULTIPLE SECTORS THEY ARE LIKELY
TO BRING INTERDISCIPLINARY
SOLUTIONS TO SCIENCE AND THROUGH
CAREER PROGRAM WE ARE ADDRESSING
THESE ISSUES AND WON'T GO OVER
ALL THESE PROGRAMS.
THIS IS A PAPER THAT
CO-AUTHORED WITH MARIE BERNARD
CHIEF OFFICE OF SCIENTIFIC
WORKFORCE AND SCIENCE POLICY AND
KELLY FROM NIH INTRAMURAL
PROGRAM AND HERE WE TALKED ABOUT
HOW CRITICAL IT IS TO HAVE ALL
FIVE DOMAINS WORKING IN A
CONCERTED COORDINATED FASHION TO
BE ABLE TO FINALLY MAKE PROGRESS
AROUND EQUITY IN OUR WORKFORCE.
WE NEED TO HAVE FLEXIBILITY
OPTIONS AND MUST HAVE A CULTURE
OF INCLUSION AND HAVE TO
DEMONSTRATE LEADERSHIP SUPPORT
AND MUST INCLUDE ACTION
ORIENTING TO ACCOUNTABILITY
MEASURES AND AS ALWAYS WE DO
THIS IN AN EVIDENCE-BASE THE
SAME WAY WE DO ANYTHING.
WE NEED TO STUDY IT IN A
RIGOROUS WAY AND DO CLINICAL
TRIALS OF INTERVENTIONS WE ARE
PROPOSING THAT IS A
SUMMARIZATION IN THIS NATURE
PAPER.
WITH THAT I WANT TO THANK ALL OF
YOU FOR YOUR TIME THIS MORNING
AND BRUCE FOR CHANGING YOUR
AGENDA TO ALLOW ME TO BE HERE
FIRST TO GO TO THE NEXT STEP
LAUNCHING NIH-WIDE WOMEN'S
HEALTH RESEARCH AND LAUNCHING
FIRST EVER FAQ SHEET TALKING
ABOUT WOMEN'S HEALTH AND
INVESTMENT AND PUBLISHING
UNDERSTUDIED UNDERREPORTED
UNDER-REPRESENTED POPULATIONS OF
WOMEN'S HEALTH DATA BOOK.
WE PUBLISH IT EVERY 10 YEARS TO
SEE POPULATIONS OF WOMEN AND
HEALTH OUTCOMES.
CHECK IT OUT ONLINE TODAY AND IT
IS MY PLEASURE TO BE HERE WITH
YOU TODAY.
>> AUDIENCE: [APPLAUSE].
>> THANK YOU SO MUCH, JANINE.
FANTASTIC PRESENTATION THAT IS A
LOT FOR US TO DIGEST.
I'M SURE THERE WILL BE MANY,
MANY QUESTIONS AND COUNCIL
MEMBERS, I GUESS DO WE HAVE A
PROTOCOL FOR THIS, DAVE?
MAYBE TURN YOUR CARD LIKE THAT
OR SOMETHING AS YOU GET IN A
LINE FOR YOUR QUESTIONS THAT
WILL HELP US INNOVATIVE
DIRECTOR.
>> I GOT THAT ENTIRELY FROM
SUSAN MARGO LEASE AT NSF THAT IS
WHAT SHE DOES AND HER CONVENTION
AND IT WORKS WELL.
>> I WANT TO MENTION I APOLOGIZE
I NEGLECTED TO MENTION THAT
[INDISCERNIBLE] COUNCIL MEMBER
IS ONLINE TODAY AND HE IS
PARTICIPATING ONLINE.
>> HOW WILL WE KNOW SHE HAS A
QUESTION.
>> WE SHOULD BE ABLE TO HEAR
HER.
>> OKAY. SHOUT OUT IF YOU HAVE
A VOICE. WE WANT TO HEAR IT.
>> I WILL. THANK YOU.
>> AWESOME. THANK YOU.
JOYCE?
>> THIS ONE, OKAY.
I THINK SO. THANK YOU SO MUCH.
THAT WAS WONDERFUL AND EXCITING
AND I'M EXCITED TO SEE THE
STRATEGIC PLAN AND HAVE A COUPLE
QUESTIONS LOGISTICALLY OF I LOVE
HOW YOU USE THE ARGUMENT 1
TRILLION DOLLARS IN 2040 AND
QUESTION IS I AGREE ALONE THAT
SHOULD BE AN ANSWER AND TRYING
TO INCENTIVIZE PEOPLE TO
UNDERSTAND HOW IMPORTANT IT IS
TO INVEST AND QUESTION IS 12
BILLION SHOWING THE REQUEST HOW
LIKELY OR WHAT CAN WE VIEW AS
COUNCIL MEMBERS AND OTHERS
WATCHING WHAT WE CAN DO TO MAKE
IT HAPPEN AND IS IT HAPPENING
AND THAT IS THE SECOND QUESTION.
>> SURE.
>> 12 BILLION DOLLARS IS NO. 1
QUESTION I'M GETTING RIGHT NOW
AND NOT SURPRISED IT IS FIRST
QUESTION AND REALLY IMPORTANT
ONE.
I THINK THAT IS A PRESIDENTIAL
REQUEST TO CONGRESS.
AND IT IS UP TO THE US CONGRESS
TO DECIDE HOW THEY WILL RESPOND
TO THAT REQUEST.
BY ASSIGNING THIS EXECUTIVE
ORDER IN LAYING OUT DIRECTIVES
THAT IS A ROADMAP TO WHAT COULD
BE DONE.
I THINK THAT THROUGH NIH EFFORTS
AND OTHERS WHERE WE TALK ABOUT
STRATEGIC PLAN AND OTHER
DOCUMENTS WHERE GAPS AND
OPPORTUNITIES ARE.
WE ARE DECLARING WHERE INCREASE
INVESTMENT MIGHT BE ABLE TO MAKE
A DIFFERENCE AND MUST GO THROUGH
THE USUAL BUSINESS PROCESSES
THAT BUDGET -- US GOVERNMENT
BUDGET GOES THROUGH AND AS
COUNCIL MEMBERS YOU ARE FEDERAL
GOVERNMENT EMPLOYEES RIGHT NOW
REMINDING YOU OF THAT.
THIS IS SOMETHING THAT ELEVATES
WOMEN'S HEALTH RESEARCH TO THE
HIGHEST LEVEL AND AS ALL
INSTITUTES AND CENTERS ARE --
WILL FOLLOW CONGRESSIONAL
PROCESS FOR APROPRIATION AND
LOOK FORWARD TO SEEING WHAT
HAPPENS IN FISCAL YEAR '25.
>> GREAT. SECOND QUESTION HAS
TO DO WITH LOGISTICS IN NIH AND
LOVE HOW YOU SAY THE IDEA OF
REALLY INTEGRATING SEX AS A
BIOLOGICAL FACTOR AND GENDER
DIFFERENCES THROUGHOUT THE
ENTIRE RESEARCH TO CLINICAL
TRIALS AND QUESTION IS, IS THAT
BEING TRICKLED DOWN TO CENTER
FOR SCIENTIFIC REVIEW AND
ORIENTATION FOR STUDY SECTION
MEMBERS WHERE THEY SEE THIS AND
NO SEE SO IT GETS IMPLEMENTED
MAKING SURE THERE IS COMPLIANCE.
>> THANK YOU FOR THE GREAT
QUESTION. WENT INTO EFFECT IN
2016 AND KNOW THAT MAKING
CHANGES AT NIH IS SORT OF LIKE
TURNING AN AIRCRAFT CARRIER
TAKES A WHILE TO DO AND
DIFFERENT FIELDS AND DISCIPLINES
AT DIFFERENT PLACES IN THIS
STORY AND OVER YEARS DEVELOPED
VARIETY OF EDUCATIONAL MATERIALS
-- TALKING ABOUT HOW TO
IMPLEMENT SBIB AND TRAINING
TRAINER VIDEOS AND INTEGRATION
TEACHING GRAD STUDENTS AND THE
LIKE AND REGARDING CSR I HAVE
BEEN IN CONVERSATION WITH
MELANIE BURNS DIRECTOR OF CSR
AROUND CURRENT NEED TO FURTHER
ELEVATE -- AS A SIMPLIFIED
REVIEW FRAMEWORK GOING INTO
EFFECT AND IS ON AGENDA FOR
TODAY AND PART OF FACTOR 2 AND
YOU WILL SEE WHERE IT FITS AND
WILL CONTINUE TO ELEVATE ISSUE
THROUGH PEER REVIEW PROCESS AND
PROGRAMATIC OVERSIGHT LOOKING AT
PROGRESS REPORTS AND LIKE AND
ENCOURAGING IT BEST WE CAN
THROUGH PUBLICATIONS AND
MENTIONING THAT TTA.GOV
REQUIREMENTS.
THOSE CLINICAL TRIALS THAT ARE
PHASE 3 CLINICAL TRIALS OR
COVERING APPLICABLE PRODUCTS
WILL HAVE RESULTS BY SEX IN
CLINICAL TRIALS.GOV AND WANT TO
GIVE YOU GOOD NEWS WHEN WE LOOK
AT PUBLICATIONS.
RATE OF PUBLICATIONS AND OF
SEX-SPECIFIC OUTCOMES FROM PHASE
3 CLINICAL TRIALS HAS BEEN
SOLVED AT 25% OF THEM.
IT IS NOW UP TO NEARLY 50%. OF
COURSE, WE WANT IT TO BE 100%.
MORE WORK TO DO THERE AND ARE
WORKING AT PEER REVIEW PHASE AND
PROGRAMATIC OVERSIGHTS AND AT
PUBLICATION RESULTS REPORTING.
>> LOOKS LIKE KEN IS VERTICAL.
>> OKAY. WONDERFUL. THAT WAS
GREAT. SUCH A FABULOUS PROGRAM.
YOU KNOW, SO BROAD.
SOY WAS CURIOUS. I SIT ON A
FORUM FOR REGENERATIVE MEDICINE.
>> COW PUT YOUR MICROPHONE
CLOSER.
>> OKAY.
>> JUST DRAG IT.
>> CAN YOU HEAR ME NOW? OKAY.
>> [INDISCERNIBLE].
>> YEAH. OKAY. GREAT. SORRY I
DON'T USUALLY HAVE TROUBLE BEING
HEARD.
>> AUDIENCE: [LAUGHING].
>> ANYWAY, SO I SIT ON THE FORUM
NATIONAL CANDIDATES FORUM FOR
REGENERATIVE MEDICINE AND VERY
BROAD COALITION OF AGENCIES AND
PATIENT ADVOCATES AND ACADEMICS
AND INDUSTRY AND IS A TOP THAK
IS STARTING TO GET LENGTH IN
BEING TALKED ABOUT AND LINDA
GRIF EDGE GAVE TALK A COUPLE
YEARS AING TO FORUM THAT STARTED
TO JUMPSTART THIS IDEA AND IS
TIMELY AND IMPORTANT AND
WONDERING I DIDN'T SEE REFERENCE
EXPLICITLY TO REGENERATIVE
MEDICINE HERE AND WONDER IF
ELEMENTS OF PROGRAM TOUCH ON
THAT.
>> THANK YOU FOR THAT QUESTION.
VIVIAN DEPUTY DIRECTOR OF OWH IN
RECENT REGENERATIVE WORKSHOP
AFFILIATED WITH EFFORT IN
NATIONAL ACADEMIES TALKING ABOUT
SEX AS A BIOLOGICAL VARIABLE.
IT IS TRICKLING IN AND HASN'T
BEEN AT FOREFRONT AND KNOW IT
ABSOLUTELY NEEDS TO BE THERE.
THERE ARE VERY WELL-RECOGNIZED
SEX DIFFERENCES IN PROLIFERATIVE
CAPACITY AND SCARRING AND ARE
HIGHLY RELEVANT TO REGENERATIVE
MEDICINE AND FIELD THAT IS
FAIRLY NEW-ISH. YOU KNOW, IT IS
IMPORTANT TO IMBED THAT
CONSIDERATION FROM THE BEGINNING
AND WOULD LOVE TO HAVE YOU LEND
YOUR VOICE TO THAT AS YOU ARE IN
THOSE SECTORS AND CORNERS AND
VENUES.
>> WE WILL WANT YOU PROBABLY TO
LEND YOUR VOICE TO OUR GROUP AS
WELL. THANK YOU.
>> HAPPY TO DO THAT.
TRANSPLANTATION FOR EXAMPLE WE
KNOW SEX DIFFERENCES AND SEX
DISCORDANCE TRANCE PLANATION
BECAUSE OF PROLIFERATIVE
DIFFERENCES AS THOUGH REALLY
ABSOLUTELY NEED TO CONSIDER T
THAT.
>> CONGRATULATIONS ON THE
PHENOMENAL PROGRESS THAT ORWH
HAS MADE AND MY QUESTION IS
ABOUT YOU HAVE MADE IT CLEAR
AMONGST MANY THINGS SEX
DIFFERENCES THAT CAN LEAD TO
DIFFERENTIAL HEALTH OUTCOMES AND
WITHIN THAT AND FOR WOMEN IN
PARTICULAR, WHAT ABOUT
ADDRESSING THESE OTHER
DIFFERENTIAL EXPERIENCES THAT
ARE RELATED TO RACE, ETHNICITY
AND SOCIOECONOMIC?
WE KNOW THAT CERTAIN -- WOMEN
FROM CERTAIN UNDERSERVED CERTAIN
HEALTH DISPARITY POPULATIONS ARE
SEVERELY IMPACTED BY
DIFFERENTIAL FACTORS THAT LEAD
TO DIFFERENTIAL HEALTH OUTCOMES.
COULD YOU SPEAK.
>> SURE.
>> SPECIFICALLY TO THE SUBSET
AND HOW THAT EFFECTS THE HEALTH
OUTCOMES.
>> THANKS SO MUCH FOR THAT
QUESTION, GILDA.
YOU KNOW, AS I MENTIONED
UNDERSTUDIED UNDER-REPRESENTED
AND UNDERREPORTED POPULATION OF
WOMEN'S HEALTH DATA BOOK IS
COMING OUT TODAY.
IN THE DOCUMENT WE TALK ABOUT
THE HEALTH DISPARITIES WE SEE
ACROSS VARIOUS POPULATIONS OF
WOMEN AND KNOW ALL WOMEN ARE NOT
THE SAME AND MEN AND WOMEN ARE
DIFFERENT AND AGES AND FACTORS
AND OTHER FACTORS YOU MENTIONED
SEVERAL OF THEM AND IS IMPORTANT
FOR US TO THINK THROUGH AND NO
THE JUST GO TO DEFAULT THIS IS A
RACIAL AND ETHNIC DIFFERENCE IN
OUTCOME.
IT IS NOT NECESSARILY AND
USUALLY NOT RELATED TO RATES
PER-SE BUT SOMETHING ELSE THAT
IS HAPPENING LIKE DISCRIMINATION
OR LIKE SOCIOECONOMIC STATUS
FACTORS AND ACCESS TO CARE
ISSUES AND MIGHT BE GENETIC
ANCESTRY ISSUES TO SEPARATE FROM
RACE AS A SOCIAL CONSTRUCT.
IT IS REALLY IMPORTANT HOW WE
THINK ABOUT THIS AND TALK ABOUT
IT AND LOOK AT THE DATA.
THAT WE LOOK AT THE DATA.
SO WE INCLUDE LOW SOCIOECONOMIC
STATUS AND INCLUDE RURAL VERSUS
URBAN LOCATIONS AND ARE MANY
COUNTIES IN THE UNITED STATES
BOTH URBAN AND RURAL THAT ARE
MATERNITY CARE DESSERTS AND PART
OF WASHINGTON, DC NOW AND
DESERTS THAT WILL EFFECT HEALTH
OUTCOMES AND CLOSEST YOU CAN
DELIVER A BABY IS HOURS AWAY.
IT IS A VARIETY OF FACTORS AND
IF YOU RECALL THAT BLUE SLIDE I
SHOWED HAD ALL OF THE FACTORS IN
ONE SLIDE.
WE NEED TO CONSIDER MANY OF
THESE FACTORS TOGETHER AND NOT
ONLY LOOK AT ONE AT A TIME.
SO WE ARE CALLING ON OUR SOCIAL
SCIENCE COLLEAGUES AND OTHERS TO
HELP US FIND WAYS TO DO THAT
BECAUSE IT CAN BE OVERWHELMING
TO SAY ALL THESE FACTORS EFFECT
HEALTH AND IS EASIER TO LOOK AT
ONE GENE AND IS NOT ENOUGH AND
IF YOU TRY TO IMPROVE HEALTH OF
EVERYONE THAT DR. BER TAN OELI
HAS SAID OVER AND OVER OUR JOB
IS NOT DONE UNTIL ALL WOMEN'S
HEALTH IS BETTER WE HAVE TO FIND
ADDITIONAL APPROACHES AND REAL
WORLD EVIDENCE AND WHATEVER
TOOLS WE CAN TO UNDERSTAND WHAT
IS BETTER AND WHAT IS HAPPENING
AND WHY.
WHEN YOU CHARACTERIZE DATA LIKE
IN DATA BOOK IT TELLS YOU WHERE
NEEDS ARE AND OPENS QUESTIONS
FOR RESEARCH AND ARE PARTNERING
WITH INSTITUTES ON UNDERSTUDIED
AND UNDERREPORTED AND
UNDER-REPRESENTED POPULATIONS OF
WOMEN PROGRAM OR RESEARCH
PROGRAM THAT IS A SUPPLEMENT AND
ALLOW INVESTIGATORS TO SEEK
ADDITIONAL FUNDING TO DIG DEEPER
AND LOOK AT QUESTIONS AND THANKS
FOR BRINGING IT UP AS YOU KNOW
THE NOTION OF ADVANCING HEALTH
EQUITY IS CRITICAL FOR THE
HEALTH OF OUR COUNTRY AND NATION
AND ECONOMIES AND EVERYTHING
ELSE WE DO.
WE ARE EAGER TO PARTNER WITH ICO
COLLEAGUES ON WAYS TO DO THAT
AND THAT SPECIFICALLY ADDRESS
WOMEN'S HEALTH AND WILL GIVE YOU
ONE DATA POINT AS I END HERE.
MATERNAL MORTALITY IN THE
COUNTRY IS HIGHEST THAN IN ANY
INCOME COUNTRY AND IS INCREASING
AND HIGHER THAN SEVERAL MIDDLE
INCOME COUNTRIES AND
UNFORTUNATELY LIKE MANY HEALTH
DATA RACIAL AND ETHNIC
DIFFERENCE WE SEE HIGHEST
MORTALITY RATES IN INDIAN ALASKA
NATIVE AND AFRICAN AMERICAN
WOMEN THREE TIMES OTHERS AND
THAT IS A DIFFERENT -- IT IS NOT
DIFFERENT BY SOCIOECONOMIC
STATUS.
WHEREAS MANY HEALTH INDICATORS
ONCE YOU PUT IT ON SBS YOU SEE
DIFFERENCE IS A WAY AND IS
TELLING US SOMETHING ABOUT OUR
SYSTEM AND WE HAVE TO BETTER
UNDERSTAND THAT THROUGH RESEARCH
AND DATA TO INFORM POLICY
DECISIONS.
SO WE STILL HAVE WORK TO DO AND
THIS GROUP IS ASKING FANTASTIC
QUESTIONS AND I'M INSPIRED WE
WILL KEEP MOVING FORWARD IN THAT
REGARD.
>> JANINE IF I COULD FOLLOW UP
ON THAT QUESTION AND I THINK IT
IS A UNIQUE STRENGTH AND
RESOURCE WITHIN OUR COMMUNITY
AND WE PARTNERED WITH YOU ON RAD
X TECH FOR MATERNAL HEALTH AND
THERE IS BUILT INTO THE
EDUCATIONAL SYSTEM AND WAY THAT
OUR STUDENTS ARE PASSIONATE
ABOUT TECHNOLOGIES WITH DESIGN
PROJECTS AND EVERYONE GOES
THROUGH DESIGN PROJECTS AND MANY
DESIGN PROJECTS ARE ORIENTED
TOWARDS UNDERSERVED COMMUNITIES
AND THEY ARE CONSTRAINED
ACTUALLY IN COSTS BECAUSE
STUDENTS DON'T GET LOTS OF MONEY
TO DO DESIGNS AND THEY ARE VERY
CLEVER IN INTEGRATING AND OF
COURSE YOU WILL KNOW AS
PRESIDENT OF ENGINEERING COLLEGE
THAT REALLY DRIVES FORWARD THAT
WHOLE DESIGN EXPERIENCE AND
WORKED ON A NUMBER OF LEVELS
THAT IS WOVEN INTO OUR
CONSCIOUSNESS AND THOSE KIDS
THAT DO THE DESIGN AND GET
HOOKED ON PROJECTS IT STICKS
WITH THEM THEIR ENTIRE LIVES AND
MANY GO ON AND BEGIN TO
COMMERCIALIZE THOSE AND IS A
SECRET POWER IT IS NOT
NECESSARILY SO SECRET IN OUR
COMMUNITY AND NOT NECESSARILY
WIDELY KNOWN OUTSIDE OF OUR
COMMUNITY.
YOU HAVE SEEN EXPRESSION OF IT
IN INTERNAL HEAL WILLING AND
BEAUTIFUL TECHNOLOGIES MORE
COMING AND FROM OUR BIASED
PERSPECTIVE IT WOULD BE GREAT IF
THERE WERE MODEST AND COST
EFFECTIVE IF WE GET ANY OF 12
BILLION.
>> RIGHT.
>> GOING INTO INVESTING IN YOUNG
PEOPLE IN THE PIPELINE THERE IS
ENORMOUS DIVERSITY IN STUDENTS
AND THEN YOU KNOW IT IN TERMS OF
KAGSD AND LEADERSHIP BRINGING
WOMEN INTO THE FEMME TECH
BUSINESS EXPANSION THAT IS A
VERY COMPELLING ARGUMENT AND
STILL DON'T SEE THAT MANY C
SUITE WOMEN AND ENGINEERS AND SO
FORTH AND THIS IS ALL PART OF
THAT PIPELINE AND THINK YOU CAN
WITH MODEST ENCOURAGEMENT EXCEED
AND EXPAND ACTIVITIES WITH
CONNECTION HERE THAT IS WITH
COUNCIL AND OUR ENTIRE
COMMUNITY.
>> THANK YOU. I AGREE
WHOLEHEARTEDLY AND ONE REASON
WHEN I FIRST MET YOU TALKING
ABOUT GROWING UP IN DC JUST THE
WAY YOU TALK ABOUT THAT.
IN INCORPORATION OF DESIGN
THINKING INTO HOW SCIENTISTS
CONVERGE AND ARE NOT TRAINED
THAT WAY AS YOU KNOW.
IT IS A POWERFUL APPROACH AND
EVERY TIME I TALK TO SOME
YOUNGER INDIVIDUALS IN THIS
SPACE I'M INSPIRED AND HOPEFUL
FOR OUR FUTURE AT RISK OF MAKING
A GENERALIZATION AND I FIND THAT
ENGINEERING COLLEGE SKILLS ARE
[INDISCERNIBLE] AND IF YOU GIVE
THEM A PROBLEM THEY WILL TRY TO
SOLVE IT AND LOVE THAT ABOUT
THEM AND INTERDISCIPLINARY
APPROACHES BRINGS TEAMS TOGETHER
NOT SITTING AROUND TABLE SAYING
FROM MY PERSPECTIVE I SEE THIS
BUT TO COME TOGETHER AND MAKE
SOMETHING REALLY NEW IS WHAT WE
ARE AFTER AND THINK IT IS NOT A
SECRET POWER BRUCE BUT YOUR
SUPERPOWER.
>> I THINK IT IS. IF YOU HAVE A
FEW MORE MINUTES I WANT TO ASK
PROBABLY THE QUESTION THAT
EVERYONE IS ASKING MAYBE.
CYNTHIA, I WILL CPU. YES?
>> OKAY. I WILL TRY TO LOOK AT
YOU AND USE THE MIC HERE AND
THANKS FOR YOUR REALLY INSPIRING
PRESENTATIONS.
I WAS POPPING UP IDEAS IN MY
HEAD AS YOU WENT ALONG.
ONE THING I'M INTERESTED IF YOU
CAN SHARE YOUR DATA ON IS THE
RELATIONSHIP BETWEEN WOMEN'S
HEALTH AND CHILDREN'S HEALTH NO
THE JUST FOR MATERNAL HEALTH AND
PRENATAL AND POSTNATAL BUT IN
SINGLE MOTHER FAMILIES AND IF
MOM IS DOWN WITH SOME AGENCIES
FAMILY IS DOWN.
WHAT KIND OF COMMENT MIGHT YOU
HAVE ON THAT LINKAGE?
>> THANK YOU FOR THAT QUESTION
ABOUT HOW HEALTH OF WOMEN
EFFECTS FAMILIES AND CHILDREN
BEYOND PREGNANCY AND MATERNAL
HEALTH ANGLE THAT IS CRITICALLY
IMPORTANT AND WHAT WOMEN ARE
EXPOSED TO DURING PREGNANCY AND
HEALTH BEFORE PREGNANCY THAT HAS
A PROFOUND IMPACT ON THE HEALTH
OF THE CHILD THROUGH EPIGENETICS
EFFECTS AND OTHERS AND WE KNOW
THAT BIOLOGY AND KNOW THAT CAN
GENERATE INTERGENERATIONAL
OUTCOME.
YOU ARE ALSO ASKING ABOUT THE
SOCIAL CONTEXT.
I'M JUST KIND OF, YOU KNOW, SAD
TO SHARE WITH YOU THAT ONE
REALLY IMPORTANT CAUSE OF
MATERNAL HEALTH IN THIS COUNTRY
IS VIOLENCE, IS DEPRESSION, IS
SUICIDE, IS SUBSTANCE OVERDOSE.
THAT IS TELLING US SOMETHING
ABOUT WHAT WE ARE DOG OR NOT
DOING TO SUPPORT PREGNANT PEOPLE
AND PEOPLE AFTER THEY DELIVER.
AND SO I DON'T THINK THAT WE CAN
MINIMIZE THE MENTAL HEALTH
CONSEQUENCES OF THE SOCIAL
DRIVERS OF HEALTH WE ARE ALL
IMBEDDED IN AND WHAT YOU ARE
GETTING TO.
WE DO SEE THE EUNICE KENNEDY
SHRIVER NATIONAL HEALTH
INSTITUTE -- LEADING FOR
SUPPORTING MATERNAL HEALTH
RESEARCH AND CHILD HEALTH
RESEARCH AND ARE ADDRESSING SOME
THINGS ABOUT THE MATERNAL DIAD
AND LEAKING DATA SETS FROM
MOTHERS AND EHRS IN
COLLABORATION WITH OFFICE OF
NATIONAL COORDINATORS AND ONE
WAY THEY LINK DATA SETS TO DO
ANALYSIS TO LOOK AT OUTCOMES.
WE KNOW WHAT HAPPENS TO AN
INDIVIDUAL IS EMBODIED IN THAT
PERSON.
IT CAN BE MEASURED THROUGH
CORTISOL LEVELS AND MEASURED
THROUGH SHORTENING TELOMERES AND
HAS A CONSEQUENCE ON PARENTING
AND LAST DATA I ADDRESSED THAT
IS NICHD FUNDED INDIVIDUAL WOMEN
THAT EXPERIENCE DEPRESSION
DURING PREGNANCY OR POSTPARTUM
ARE MORE LIKELY TO HAVE A
CARDIOVASCULAR EVENT AFTER THE
DELIVERY UP TO A YEAR LATER AND
HAS TO HAVE AN EFFECT ON THE
FAMILY IF THE MOTHER IS NOT
AVAILABLE AND IS ILL.
THANKS FOR BRINGING UP THAT
REALLY SALIENT POINT NOT ABOUT
THE BIOLOGY AND HAVE TO CONSIDER
THAT AND ALSO IS ABOUT THE
SOCIAL FACTORS AND WHEN YOU
ADDRESS HEALTH OF WOMEN YOU
ADDRESS HEALTH OF FAMILIES AND
COMMUNITIES AND SOCIETIES
WHETHER ECONOMIC BENEFIT OR
STABILITY BENEFIT BECAUSE OF
CHILDREN IN FAMILY AND OTHER
INDIVIDUALS AND WOMEN ARE
PRIMARY CAREGIVERS OF ALL FAMILY
MEMBERS IN THE COUNTRY AND IS A
GENDERED BEHAVIOR AND ALSO HAS
CONSEQUENCES ON THOSE WOMEN TO
HELP THEMSELVES COMPLICATED
IMPORTANT TO ADDRESS AND
INSPIRED THAT YOUR COUNCIL ASKED
SO MANY GREAT QUESTIONS THINKING
ABOUT ISSUES FROM SO MANY
VANTAGE POINTS AND THAT IS WHAT
WE NEED AND BRUCE IS A GREAT
PARTNER AND LOOK FORWARD TO
WORKING WITH ALL INSTITUTES TO
BRING THEIR EXPERTISE TO THESE
ISSUES.
THANKS FOR THAT QUESTION.
>> THANK YOU. DO YOU HAVE TIME
FOR ONE MORE QUESTION.
>> ONE MORE.
>> I CAN ASK YOU QUESTIONS
ANYTIME.
>> THIS IS GREAT AND KNOW YOU
MENTIONED DATA IS A KEY PART OF
THIS LIKE YOU MENTIONED AI AND
MACHINE LEARNING AND ALSO WHEN
YOU MENTIONED RAD X I REMEMBER A
CHALLENGE YOU SAID WAS BRINGING
TOGETHER DATA SETS THEY TALK TO
EACH OTHER AND YOU MENTIONED
WORLDWIDE EFFORTS AND WONDER
WHAT EFFORTS AT NIH AND PARTNERS
AND IN TERMS OF BEING ABLE TO
MAKE THIS ACCESSIBLE I GUESS FOR
PRACTICAL ISSUES OF DATA AND
SHARING DATA THAT IS SIMILAR I
GUESS TO THE HUMAN GENOME
PROJECT AND YOU PROBABLY KNOW
THAT TOOK YEARS FOR THEM TO SET
UP ALL THAT AND WONDERING FROM
LOGISTICS STANDPOINT HOW THAT
DATA OR INFORMATION TO BE SHARED
OR WHAT CHALLENGES YOU MADE.
>> I WILL GIVE YOU THIS IN A
SECOND AND GIVING YOU A HEADS UP
AND IN TERMS OF WOMEN'S HEALTH,
DURING COVID WE DEMONSTRATED WE
COULD MOVE PAST AND MERGE DATA
SETS AND OTHER EFFORTS USING
ELECTRONIC HEALTH RECORDS DATA
AND WAY WE WERE ABLE TO SEE
PREGNANCY OUTCOMES WERE WORSE
WITH COVID.
WE HAVE TO DO THE SAME FOR
EVERYTHING IN A SAFE WAY THAT
EFFECTS OR PROTECTS PRIVACY.
WE HAVE NIH-WIDE DATA SHARING
POLICIES THAT HAVE BEEN RULED
OUT FAIRLY RECENTLY AND P SET IS
DIFFERENT FOR WOMEN'S HEALTH WE
NEED COMMON DATA ELEMENTS IN
DATA SETS SO DATA WILL BE
INTEROPERABLE AROUND AGE OF
MENSTRUATION AND MENOPAUSE
STATUS DID YOU HAVE PREECLAMPSIA
DURING PREGNANCY AND ASKING A 50
YEAR OLD WOMAN THAT IS SOMETHING
NOT THAT TYPICAL AND RELATED TO
HER RISK FOR CARDIOVASCULAR
DISEASE AND STROKE AND IF WE
DON'T HAVE QUESTIONS OF E HAD.
RS WE CAN'T ANALYZE DATA AND OUR
VANTAGE POINT IS IMBEDDING CDES
AND PERSPECTIVES INTO DATA SETS
SO THEY WILL BE IN FORMS AND
INTEROPERABLE AND WE CAN ANSWER
MORE QUESTIONS AND BRUCE HAVE
ANYTHING TO ADD FOR JOYCE FOR
THAT.
>> NO. THAT IS AN ENORMOUS
EFFORT AND INCREDIBLY VALUABLE
ONE THAT BEGINS TO INFORM HOW WE
USE EHS AND CRITICAL COMPONENTS
HOW WE WILL GET EHR AS AN
INFORMATION GENERATING
ULTIMATELY TO HELP FACILITATE
DECISIONS AND MY QUESTION IS A
LITTLE ABOUT THAT A LOT OF
EXCITEMENT AND CONFUSION IN
WOMEN'S HEALTH IS SURROUNDING
SORT OF THE HOFRM OWN RELACEMENT
THERAPY DISCUSSION AND OVER TIME
IF YOU TRACK IT CH. I'M INTERED
IN YOUR THOUGHTS ON THAT CLASSIC
CHALLENGE TO GET INFORMATION AND
FRUSTRATING WHEN YOU SEE YOU CAN
MAKE A DECISION WITH YOUR CARE
PROVIDER AND ASSESS RISKS AND
HOPE CARE PROVIDER HAS GUIDANCE
AND CANCER NATIONAL CONTROL
NETWORK AND THESE ARE GUIDELINES
AND CONDITION AND WHAT YOU
SHOULD DO FOR TREATMENT AND FEEL
THIS AREA IS CONFUSING AND
HAVING BEEN INVOLVED IN BREAST
CANCER RESEARCH FOR MANY YEARS I
THOUGHT I UNDERSTOOD IT AT ONE
POINT AND DIDN'T UNDERSTAND IT
AND THOUGHT I DID AND OSCILLATES
IT AND LIKEN TIRE DISCUSSION
TODAY WITH THE PUBLIC AND WHAT
ARE THOUGHTS ON THAT AND GETTING
TO GREATER CLARITY WITH
RECOMMENDATIONS FOR INDIVIDUALS
AND WHAT WE ACTUALLY NEED RATHER
THAN THAT SORT OF PHRASED MAKE A
DECISION WITH THE DISCUSSION
WITH YOUR PROVIDER.
>> RIGHT. BRUCE, THIS IS AN
IMPORTANT TOPIC AND TIMELY AND
OVER 30 YEARS AGO BERN ADEAN
HEELY CREATED WOMEN'S HEALTH
INITIATIVE THAT IS AN INCREDIBLE
INVESTMENT IN TIME AND MONEY AND
EFFORT AND INDIVIDUALS
PARTICIPATING AND CONTINUES WITH
A FOLLOW UP STUDY AND WAS
DESIGNED TO LOOK FOR VERY
SPECIFIC QUESTIONS ABOUT
CONJUGATED [INDISCERNIBLE] AND
WHICH IS WHAT WAS AVAILABLE AT
THE TIME TO INDIVIDUALS OVER 60
AND POST MENOPAUSAL IN TERMS OF
PREVENTION OF CHRONIC DISEASE
AND WAS A RANDOMIZE CHONDRTROLL
TRIAL WITH OTHER STUDIES AND
ANSWERS THOSE QUESTIONS AND LEFT
US ALSO WITH MORE QUESTIONS,
SOME OF WHICH HAVE NOT YET BEEN
ANSWERED AND OF COURSE SCIENCE
HAS CONTINUED AND WE NOW HAVE
HAD MORE FORMULATIONS WESTO
GENERALS AND PHYTOEST ROEJENS
AND FORMULATIONS OF PROGESTERONE
AND PERMUTATIONS AND WANT TO
UNDERSTAND BETTER WHEN TIMING
WHEN MENOPAUSAL HORMONE THERAPY
WHEN IT STARTED AND MIGHT BE
IMPORTANT AND UNDERSTAND BETTER
BRAIN EFFECTS AND AREA AND
READING PAPER AND HAVE QUESTIONS
LIKE I DID BEFORE AND WHAT I
WILL SAY IS THERE IS SO MANY
MORE QUESTIONS RIGHT NOW AND
SCIENCE HAS GIVEN US THOSE
QUESTIONS.
BUT WE NEED TO BE ABLE TO GIVE
WOMEN ANSWERS AS YOU SAID.
TO DO THAT WE NEED TO WORK
TOGETHER ACROSS INSTITUTES TO
DESIGN A COORDINATED STRATEGY
AROUND MENOPAUSE.
THIS PATHWAY TO PREVENTION
PROGRAM THAT WE ARE STARTING
WILL HELP US DO THAT IN A
THOUGHTFUL AND METHODICAL AND
DATA-DRIVEN WAY AND TAKES TIME
AND IS HARD TO WAIT FOR THAT
INFORMATION.
I THINK THAT WE ARE GOING TO
HAVE TO WORK TOGETHER IN
DIFFERENT WAYS AND APPLAUD THE
NATIONAL INSTITUTE ON AGING FOR
THE MANY STUDIES THAT THEY
SUPPORTED THUS FAR LIKE
MRS. FLASH AND THEY TESTED
INTERVENTIONS AND WE NOW HAVE
MULTIPLE INTERVENTIONS FOR MOTOR
SYSTEM AND BROUGHT MORE
QUESTIONS AS WOMEN THAT HAVE
PROMINENT BASED MOTOR SYSTEMS
CARDIOVASCULAR DISEASE WORSENING
AND HAVE MORE QUESTIONS AGAIN
AND THINK WE NEED A MENOPAUSE
ALE RESEARCH STRATEGY INVOLVING
MULTIPLE INSTITUTES AND CENTERS
THAT IS INTERDISCIPLINARY
COORDINATED AND LOOK FORWARD TO
PATHWAYS PREVENTION PROGRAM TO
HELP US MOVE IN THAT DIRECTION
AND WAS PARTICULARLY PLEASED TO
SEE MID LIFE HEALTH OF WOMEN
CALLED OUT IN THE EXECUTIVE
ORDER AND IMPORTANCE OF
UNDERSTANDING THAT THE
MENOPAUSAL TRANSITION IS A
HEALTH INFLECTION POINT THAT
MARKS A SUBSTANTIAL MOMENT WHERE
THE RISK FOR CHRONIC DISEASE
ACCELERATES MEANING IT IS A
POTENT OPPORTUNITY TO INTERVENE.
LIKE PREGNANCY IS A STRESS TEST
HEALTH INFLECTION POINT
MENOPAUSE TRANSITION IS A HEALTH
INFLECTION POINT AND WE HAVE TO
PAY MORE ATTENTION TO IT.
>> THANK YOU JANINE. YOU ARE
OFF THE HOOK AND WE ARE VERY,
VERY GRATEFUL FOR YOU COMING
HERE.
>> THANK YOU, BRUCE.
>> WE KNOW DAVE POINTED OUT
PRESS RELEASE CAME OUT AT 10:07.
>> PERFECT TIMING.
>> YOU ARE LIVE AND CAN GO
RESPOND TO THE ENTIRE COUNTRY.
WE ARE SO THANKFUL YOU CAN COME
HERE AND GIVE US A PREVIEW OF
THAT AND INSPIRE LOTS OF
THINKING AND WE LOOK FORWARD TO
EXPANDING OUR COLLABORATIONS
WITH YOU AND OUR COMMUNITY IS,
YOU KNOW, A RESOURCE THAT WE ARE
HOPING YOU CAN CONTINUE TO RAI
LIE ON.
>> THANK YOU BRUCE AND JILL AND
DAVID FOR LEADERSHIP AND
INSTITUTE THAT HAS BEEN FROM THE
BEGINNING SINCE YOU CAME, BRUCE,
OPEN TO THE CONVERSATIONS AND
EXCITED ABOUT HEARING FROM NIWHS
IDEAS PUTTING SCIENCE AND
TECHNOLOGY AND ENGINEERING AND
IMAGING AND TOOLS TO WORK WITH
[INDISCERNIBLE] AND PLEASURE BE
WITH ALL OF YOU AND LOOK FORWARD
TO WORKING WITH ALL OF NEW
CAPACITY AND THRILLED NEW
NIH-WIDE RESEARCH FOR HEALTH OF
WOMEN 2024 TO 2028 IS NOW LIVE.
THANKS SO MUCH.
>> AUDIENCE: [APPLAUSE].
>> THANK YOU SO MUCH, JANINE AND
TO JOYCE AND JANINE AND STAFF
AND QUESTION ABOUT PEER REVIEW.
>> GOOD TO GO, RYAN? THANKS.
THANK YOU, RYAN. I WOULD LIKE
TO INTRODUCE DIRECTOR OF NIBIB'S
SCIENTIFIC REVIEW SHARING
INFORMATION ON PROJECT BRANDS
AND CONDIT REVISIONS TO FELLOWS
APPLICATIONS.
>> THANK YOU. I'M DIRECTOR OF
SCIENTIFIC OFFICE AND I WOULD
BEFORE I GO TO MY TOPIC WOULD
LIKE TO TAKE THIS OPPORTUNITY.
>> COULD YOU GET CLOSER TO THE
MICROPHONE.
>> IS THAT BETTER.
>> THANK YOU.
>> SO I WOULD LIKE TO TAKE THIS
OPPORTUNITY TO INTRODUCE THE
OFFICE OF SCIENTIFIC REVIEW.
SO MANY OF YOU KNOW OR IF YOU
DON'T KNOW WE HAVE IN HOUSE AT
NIBIB OWN OFFICE OF SCIENTIFIC
REVIEW AND APPLIED AS OUR OWN
AND SOME ARE HERE.
SOME ARE ON THE LINE ON ZOOM.
DR. JOAN HAYES. IF YOU ARE
HERE, STAND UP AND SHOW
YOURSELF.
DR. YOUNG JONES AND
[INDISCERNIBLE] AND DR.
[INDISCERNIBLE] IN OUR
INDISPENSABLE SUPPORTS.
SO WE ARE [INDISCERNIBLE] AND
ONLY 5SROS AND WE ARE BUSY AND
WHAT DO WE DO HERE? CONTINUOUS
PROGRAMS WE MANAGE ARE CAREER
DEVELOPMENT AWARDS AND NIH
RESEARCH TRAINING PROGRAMS TO 32
AND 35 AND NIH SUPPORTS RESEARCH
EDUCATION THAT INCLUDES
TEAM-BASED DESIGN FOR BIOMEDICAL
OR BIOENGINEERING PRODUCTS AND
RESEARCH EDUCATION EXPERIENCE
AND RESEARCH SUPPORT AND NIHLIP
PAYMENT PROGRAMS AND WE ARE
DOING SPECIAL PROGRAMS WITH
MULTIPLE [INDISCERNIBLE] DATE
AND ONE IS NIBIB SIGNATURE
PROGRAM FOR P41 NATIONAL CENTERS
OF BIOMEDICAL ENGINEERING.
WE ARE PART OF THE REVIEW TEAM
FOR BRAIN INITIATIVE RFAS AND
CURRENTLY HAVE THREE OF THEM AND
ARE EXCITED TO DO
NON-TRADITIONAL PROGRAMS ALWAYS
AND ONE IS DURING NSF AND NIH
INITIATIVE AND WE
[INDISCERNIBLE] WITH CYBER
PHYSICAL SYSTEMS AND NATIONAL
BODY INITIATIVES AND SOME COMING
UP IN THE PIPELINE.
SO IN 2024 AND 2025 WE HAD AND
REVIEWED ALREADY AND WILL REVIEW
NEW RFAS AND THE REST IS HERE
BIOMEDICAL NETWORKS USED
TECHNOLOGY DEVELOPMENT TO USE
HEALTH DISPARITIES AND ENHANCE
DATA AND HISTORICALLY BLACK
COLLEGES AND UNIVERSITIES AND
RESEARCH AND BIOETHICAL ISSUES
RELATED TO BIONICS AND ROBOTIC
DEVICE DEVELOPMENT AND
[INDISCERNIBLE].
SO YOU SEE WE ARE BUSY HERE AND
MUST SAY WE DON'T HAVE STUDY
SECTIONS AND REVIEW PANELS ARE
SPECIAL EMPHASIS PANELS AND SROS
ARE RECRUITING EVERY SINGLE
REVIEWER AND WE REALLY
APPRECIATE WHEN PEOPLE ARE
RESPONDING TO INVITATION AND I
WOULD BE HAPPY TO HELP YOU.
AND WE DON'T HAVE SPECIALLY
ESTABLISHED PROGRAM SPSR HAS.
WE HAVE A SEPARATE E-MAIL.
WE REALLY APPRECIATE WHEN PEOPLE
ARE SENDING US REQUESTS AND
INTERESTS AND SHARING WITH
COLLEAGUES AND INSTITUTIONS AND
IS ESPECIALLY VERY HELPFUL AND
BENEFICIAL TO PEOPLE IN THEIR
EARLY-STAGE CAREER.
NOW LET'S GO TO MY TOPIC TODAY.
NIH RE-CORRECTLY PLANNED FOR
IMPLEMENTATION AND SIMPLIFYING
REVIEW FRAMEWORK FOR RESEARCH
PROJECT GRANT AND ALSO AT SAME
TIME WE ARE DOING REVISIONS TO
THE NIH FELLOWSHIP APPLICATION.
AND REVIEW PROCESS.
AND THAT I WILL COVER THOSE TO
IMMEMENTATION PLANS TO -- IN MY
TALK TODAY.
WHAT WAS MOTIVATION FOR
EXAMINING APPLICATION REVIEW?
ORGANIZATION OF PEER REVIEW
CRITERIA HAS BECOME TOO COMPLEX
AND HEARD PERSISTENCY FEEDBACK
FROM REVIEWERS AND ALSO ABSORBED
BY NIH STAFF.
THERE WAS ALSO IN PAST DECADE
EXPANSION OF ADMINISTRATIVE AND
QUALITY COMPLIANCE REVIEWS TO
ADDRESS COMPLIANCE AND ALL THIS
DETRACTED ATTENTION AND WENT FOR
CRITICAL ROLE OF PEER REVIEW TO
EVALUATE SCIENTIFIC AND
TECHNICAL MERIT OF THE PROJECT
AND WAS ALSO APPEARANCE OF UNDUE
INFLUENCE OF REPUTATION IN NIH
PEER REVIEW AND CONCERNS RAISED
BY COMMUNITY AND OBSERVED BY NIH
STAFFING LEADERSHIP AND ALL THIS
EFFECTS JUDGMENT OF MERIT WHEN
WELL-KNOWN RESEARCHERS OR PLACES
ARE GIVEN A PATH AND LESS KNOWN
ARE TREATED WITH MORE SCRUTINY
AND ADDRESSING CHALLENGES AND
NIH HAS DECIDED TO SIMPLIFY
REVIEW FRAMEWORK FOR RPGS AND
RESEARCH PROJECT APPLICATIONS.
AND GOALS OF THESE CHANGES,
THERE ARE THREE GOALS.
FIRST, ENABLE REVIEWERS TO
BETTER FOCUS ON ANSWERING THE
KEY QUESTIONS.
SCIENTIFIC AND TECHNICAL MERIT
AND SHOULD PROPOSED RESEARCH
PROJECT BE CONDUCTED AND CAN
PROPOSED RESEARCH PROJECT BE
CONDUCTED?
THE SECOND GOAL IS TO MITIGATE
THE EFFECT OF REPUTATIONAL BIAS
AND THIRD GOAL IS REDUCING
REVIEWER'S BURDEN AND FIRST
INTENTION OF ACTIONS WERE
PUBLISHED IN OCTOBER OF 20203.
THIS IS HYPERLINK YOU CAN CHECK
DETAILS AND CHANGES ARE COMING
AT END AND WHAT IS CHANGES? IT
EFFECTS ALL RPGS WITH R ACTIVITY
CODE AND ALSO CORPORATE
AGREEMENTS AND R01 AND R03, R15,
R21, ET CETERA AND BIPHASIC
AWARDS AND MUST SAY THAT THESE
EFFECTS OR CHANGES ARE IMPACTING
ONLY SINGLE COMPONENT
APPLICATIONS AND MULTICOMPONENT
APPLICATIONS EVEN THOUGH THEY
MIGHT USE STRUCTURE OF R01 IN
APPLICATIONS AND WOULD BE STILL
REVIEWED UNDER THE OLD CRITERIA.
WHEN WILL THIS BE COMING?
IT WOULD EFFECT ALL APPLICATIONS
COMING FOR DUE DATE ON JANUARY
252025 AND AFTER. IT WILL
EFFECT SOME PEER REVIEW 20205.
YOU WILL SEE THE RESULTS IN
OCTOBER OF 2025.
SIMPLIFIED FRAMEWORK IMPACTS
REVIEW PROCESS AND WILL HELP AND
IMPROVE THE EXPECTATION IS THAT
IT WILL IMPROVE A REVIEW FOCUS
EXISTING FIVE REVIEW CRITERIA TO
BE REORGANIZED INTO THREE
FACTORS AND SOME ADDITIONAL
REVIEW CRITERIA WILL BE 2 OR ONE
FACTOR AND FACTOR 2 AND I WILL
IN A MINUTE EXACTLY WHICH ONE.
REDUCE THE SECOND EXPECTATION TO
THAT IT WILL REDUCE REPUTATIONAL
BIAS AND BY INVESTIGATIVE
ENVIRONMENT THAT WILL BE
EVALUATED IN SUCCESSION OR GAPS
IDENTIFIED AND THIS FACTOR WILL
NOT RECEIVE INDIVIDUAL SCORE BUT
WILL EFFECT SCORE.
AND THE SECOND WAS MENTIONED IN
THE GOAL IS IT SHOULD REDUCE
BURDEN AND MOST ADDITIONAL
REVIEW CONSIDERATION WILL BE
SHIFTED FROM REVIEWER TO NIH
STAFF.
ALL THIS SHOULD IMPROVE
IDENTIFICATION OF STRONGEST AND
POTENTIALLY HIGH-IMPACT
RESEARCH.
HOW IT WILL BE FOR REVIEWERS
WHEN THEY COME THROUGH AROUND
TIME TO REVIEW APPLICATION.
SO FIVE REVIEW CORE CRITERIA
WILL BE GOOD IN THREE FACTORS AS
I SAID.
FIRST FACTOR WILL ADDRESS
IMPORTANCE OF THE RESEARCH.
BY EVALUATION OF [INDISCERNIBLE]
INNOVATION AND IT WILL RECEIVE A
SEPARATE SCORE FROM
[INDISCERNIBLE].
SECOND FACTOR, FACTOR TO ADDRESS
RIGOR AND FEASIBILITY AND BY
EVALUATING APPROACH WHICH WILL
INCLUDE INCLUSION OF HUMAN
SUBJECT STUDY GROUP AND STUDY
TIMELINE FOR CLINICAL TRIAL.
IT WILL ALSO RECEIVE A SEPARATE
SCORE.
FACTOR 3, IT WILL ASSESS
EXPERTISE AND RESOURCES BY
EVALUATING INVESTIGATORS AND
ENVIRONMENT.
IT WILL BE EVALUATED APPROPRIATE
OR GAPS IDENTIFIED.
IF GAPS, ARE AN EXPLANATION THAT
WILL BE NEEDED.
FACTOR 3 WILL NOT RECEIVE A
SEPARATE SCORE BUT WILL BE
CONSIDERED FOR OVERALL IMPACT
SCORING.
SO IF YOU GO TO ADDITIONAL
REVIEW CRITERIA THAT ARE
CURRENTLY NOT SCORED BUT CAN
EFFECT OVERALL SCORE.
AS I ALREADY SAID, STUDY
TIMELINE WILL BE MOVED TO FACTOR
2 AND REVIEWS SHOULD ADDRESS
AWARD INCLUSION GROUPS THAT ARE
IN PLAN FOR RECRUITMENT.
ALSO, STUDY TIMELINE FOR
CLINICAL TRIALS WILL BE
CONSIDERED AND REVIEWED
EVALUATING FACTOR 2.
WHAT WILL REMAIN HERE IS HUMAN
SUBJECT PROTECTION SECTION AND
BIOHAZARDS AND SUBMISSIONS RENEW
AND REVISIONS AND ALL THIS WILL
REMAIN FOR ADDITIONAL REVIEW
CRITERIA THAT WILL EFFECT
OVERALL IMPACT SCORE ADDITIONAL
REVIEW CONSIDERATION THAT DON'T
RECEIVE A SEPARATE SCORE OR
IMPACT OVERALL SCORE, THEY WILL
BE TRAINED SIGNIFICANTLY.
[INDISCERNIBLE] WILL BE REMOVED
AND WILL SHIFT TO PROGRAM STAFF
AND WILL EVALUATE POST REVIEW
SELECTION AND AGENTS AND
RESOURCE SHARING PLAN AND REVIEW
TO ADDRESS INDICATION OF
BIOCHEMICAL [INDISCERNIBLE] AND
PERIOD OF SUPPORT AND THIS IS
ONE-STOP SHOP THAT IS JUST A
BUSINESS LIFE AND TO GIVE YOU A
COMPARISON AND LEFT SIDE YOU SEE
CRITERIA REVIEW CRITERIA REVIEW
CONSIDERATION FOR BEFORE JANUARY
2025 THAT WE HAVE CURRENTLY AND
ON THE RIGHT SIDE THESE ARE ONES
THAT ARE HOW THEY WILL BE
ORGANIZED AND WILL SEE AFTER
JANUARY 2025.
NIH DEVELOPED COMPREHENSIVE
WEBSITE HAVING A LOT OF
INFORMATION.
IT IS UPDATED ON A DAILY BASIS
AND WE -- THEY -- WE OFFERED
WEBINARS THAT ARE ALL RECORDED
AND AVAILABLE ONLINE TO WATCH
LATER.
HERE ARE SOME LINKS TO THE BLOG
OF OFFICE OF [INDISCERNIBLE]
RESEARCH AND LINKS TO THE PO
POLICY.
SO LET'S MOVE TO NEXT TOPIC
REVISIONS OF NIH FELLOWSHIP
APPLICATIONS AND REVIEW
CRITERIA.
AS I SAID, IT IS DONE IN
PARALLEL.
IT IS HAPPENING AT THE SAME
TIME.
RPGS CHANGES EFFECTS ALL THIS
REVIEW CRITERIA.
NOTHING CHANGES WHEN APPLICANTS
-- RESEARCHERS ARE PREPARING
THEIR APPLICATIONS.
FELLOWSHIPS, THERE ARE MORE
SIGNIFICANT CHANGES.
BECAUSE IT EFFECTS APPLICATION
CELLS AND REVIEW CRITERIA AND
THEY ARE BASICALLY SAME AND
BETTER FOCUS REVIEWERS ATTENTION
ON THREE KEY ASSESSMENT
FELLOWSHIP CANDIDATES
PREPAREDNESS AND POTENTIAL AND
RESEARCH TRAINING PLAN AND
COMMITMENT TO CANDIDATES AND
SECOND IS TO ENSURE THAT A BROAD
RANGE OF CANDIDATES AND RESEARCH
TRAINING COULD BE RECOGNIZED AS
MERITORIOUS BY CLARIFYING
SIMPLIFYING LANGUAGE IN
APPLICATION AND IN REVIEW
CRITERIA.
AND, AGAIN, REVIEWS BIAS IN
REVIEW BY EMPHASIZING COMMITMENT
TO THE CANDIDATE WITHOUT
CONSIDERATION OF SPONSOR AND
INSTITUTIONAL REPUTATION.
SO AND THIS IMPLEMENTATION OF
THIS WAS FIRST ANNOUNCED
RECENTLY IN APRIL 2024.
WHAT IS CHANGING? REVISED
FELLOWSHIP APPLICATION
STRUCTURES AND FORMS TO
APPLICANT AND APPLICATIONS WILL
BECOME SHORTER AND MORE
STRUCTURED ALIGNED WITH NEW
REVIEW CRITERIA LESS EMPHASIS
WILL BE GIVEN TO SPONSOR TRACK
RECORD AND MORE EMPHASIS ON
RESEARCH TRAINING PLAN AND
CANDIDATES PREPAREDNESS FOCUS ON
CANDIDATES NOT THE MENTOR.
DEFINE EACH SECTION THAT WILL
GIVE A DEFINITION WHO SHOULD
AUTHOR THE SECTION AND THERE
WILL BE ALSO UPDATED
INSTRUCTIONS FOR REFERENCE
LETTERS.
SO IN ADDITION TO THE
APPLICATION FORMS THERE WILL BE
REORGANIZED FELLOWSHIP CRITERIA.
THERE WILL BE THREE CRITERIA
CANDIDATES PREPAREDNESS AND
POTENTIAL TO BETTER IDENTIFY
PROMISING YOUNG SCIENTISTS.
THE RESEARCH TRAINING PLAN THAT
WILL FOCUS ON RESEARCH PROJECT
IN TERMS OF -- IT IS THERE TO
TRAINING PROMISING TO TRAIN
PROMISING SCIENTISTS AND
COMMITMENT TO CANDIDATES THAT
FOCUS ON SPONSORING
INSTITUTIONAL ENVIRONMENT
CONTRIBUTIONS TO THE CURRENT
CANDIDATES RESEARCH TRAINING
PLAN AND EMPHASIZE TRACK RECORD
AUTHOR OR IN INSTITUTION AND
WILL APPLY TO ALL FELLOWSHIPS,
AGAIN, COMING JANUARY 25, 2025.
FOR THE PARENTS, FELLOWSHIP
APPLICATIONS, IT WILL BE FOR DUE
DATE APRIL 8, 2025 THAT WILL BE
REVIEWED IN SUMMER OF 2025.
THIS IS, AGAIN, ONE EXAMPLE TO
SHOW WHAT WE HAVE CURRENTLY ON
THE LEFT SIDE.
WE HAVE CURRENTLY FIVE REVIEW
QUESTIONS AND FELLOWSHIP
APPLICATIONS THAT WILL BE
REORGANIZED AND WILL REMAIN IN
TWO ONLY.
AGAIN, FIRST WILL BE CANDIDATE
PREPAREDNESS AND POTENTIAL
RESEARCH TRAINING PLAN AND
COMMITMENT TO CANDIDATES AND
EVERYTHING WILL BE FOCUSED ON
CANDIDATE AND NO CHANGES FOR
ADDITIONAL REVIEW CRITERIA OR
REVIEW FOR FELLOWSHIP AND
FELLOWSHIP APPLICATION CHANGES
AND REVISIONS IS A SEPARATE
WEBPAGE WITH ALL OF THE
INFORMATION.
AND YOU CAN FIND ANYTHING THERE
IN QUESTIONS AND THERE IS
INFORMATION THERE TO GET TO
IMPROVE SOMEONE AND INCLUDED
THESE LINKS AND HYPERLINKS TO
THESE PAGES AND ALL OF THE
USEFUL INFORMATION AND FIRST
WEBINAR FOR WHAT FELLOWSHIP
APPLICANTS THAT WILL BE HELD IN
SEPTEMBER 19 AND REGISTRATION
AND ALL THESE WEBINARS ARE
RECORDED AND ARE AVAILABLE FOR
REVIEW TO WATCH LATER.
ON THAT, THANKS FOR YOUR
ATTENTION.
I'M HAPPY TO TAKE YOUR
QUESTIONS.
>> AUDIENCE: [APPLAUSE].
>> I'M GETTING USED TO THIS NEW
METHOD. THANK YOU. SIMON.
>> THANK YOU FOR THAT OVERVIEW
OF THE UPCOMING CHANGES.
I HAD A QUESTION THAT IS RELATED
TO THE REPUTATIONAL BIAS ISSUES.
ABOUT FIVE YEARS AGO I
PARTICIPATED IN A THEATRE STUDY
TO LOOK AT BLINDED OR
ANONYMIZATION DURING THE REVIEW
PROCESS AND WONDER WHAT CAME OF
THE STUDY.
>> THE -- THAT -- TECHNICALLY,
THEY SAID IF -- IT IS VERY
DIFFICULT TO IMPLEMENT.
THERE IS A NEED TO SEE WHO IS
DOING RESEARCH; RIGHT?
SO THEY -- THAT PILOT WENT
WITHOUT ANY IMPLEMENTATION, I
WOULD SAY.
I -- I CHECKED MICHAEL'S BLOG
THAT HE OPENED WHEN IT WAS
ISSUED.
THERE WAS VERY VIOLENT RESPONSE
FROM THE COMMUNITY AND ONLY
THREE POSTS AND ONE WAS FROM
INVESTIGATOR WHO SAID MAYBE WE
SHOULD JUST REMOVE PIS OR
ENVIRONMENT FROM REVIEWS. YOU
KNOW, TO SEE. SO, COMPLETELY
[INDISCERNIBLE].
>> RIGHT.
>> BUT IT -- IT DIDN'T GO
ANYWHERE.
THERE WAS TECHNICAL ISSUES.
>> I AGREE WITH CHALLENGES OF
DOING IT AND WOULD HAVE BEEN
INTERESTING TO SEE DATA
PUBLISHED FROM THE STUDY.
SAME GRANTS REVIEWED WITH
INVESTIGATION THERE OR
INFORMATION WITHOUT.
I WOULD BE INTERESTED TO SEE TO
WHAT EXTENT THE SCORE HAS
CHANGED.
>> I.
>> I NEVER SAW DATA PUBLISHED
FROM THAT.
>> I'M NOT AWARE OF WHERE THIS
DATA GOES.
I MEAN, PRIOR FROM
[INDISCERNIBLE].
>> THANK YOU.
>> YEAH.
>> YES. I JUST WANT TO SAY THAT
I THINK THIS SEEMS LIKE A
FANTASTIC INITIATIVE.
I -- I THINK THAT SIMPLIFYING IN
THIS WAY MAKES SENSE TO ME,
ANYWAY.
I'M WONDERING WHAT THE THOUGHT
IS ABOUT EDUCATING REVIEWERS
ABOUT THIS.
I THINK THERE ARE -- THERE IS A
TENDENCY FOR PEOPLE TO RESHUFFLE
CRITERIA IN THEIR HEADS AND
REVIEW THE SAME WAY THAT THEY
ALWAYS REVIEWED AND THOUGHTS
ABOUT THAT?
>> THAT IS A GREAT POINT.
>> YEAH.
>> AND THERE IS ALWAYS A LOT OF
WORK FOR SCIENTIFIC
[INDISCERNIBLE] TO EDUCATE
REVIEW AND PUSH THEM AND TRAIN
AND PROVIDE INFORMATION AND
DOCUMENTS AND MAKE THEM TO, YOU
KNOW, USE IT, REALLY USE IT.
SO I WAS HERE IN NIH IN 2009
WHEN THERE WAS A SIGNIFICANT
CHANGE THAT WAS 15 YEARS LATER
WE ARE HERE AND CHANGING AND WE
ARE TRYING OUR BEST.
THERE WILL BE -- THERE WILL BE
WEBINARS AND TRAINING VIDEOS
THAT ARE DEVELOPED FOR REVIEWER
AS WELL AS INFORMATION AND
GUIDANCE FOR SROS TO ENFORCE
THOSE CHANGES.
WE ARE TRYING OUR BEST.
WE IN OUR OFFICE, IT IS BECAUSE
-- AS I SAID, WE HAVE SPECIAL
EMPHASIS PANELS AND EVERY
REVIEWER AND CHAIR WE HAVE TO
TRAIN.
SO WE DEVELOP CHAIR CHEAT SHEET
SO WHEN THEY ARE -- REVIEWERS
ADDRESS AND EVALUATE, WE TELL
THEM IF THEY DID NOT MENTION IT,
PLEASE ASK THEM THIS QUESTION.
PARTICULARLY SEX AND BIOLOGICAL
VARIABLES AND WHAT STUDY GROUPS
ARE INCLUDED AND EXCLUDING ANY
GROUPS AND DO THEY HAVE
JUSTIFICATION AND WHAT DO YOU
THINK?
WE ALWAYS TRY TO ADDRESS EVERY
SINGLE POINT THAT THEY ARE
REQUIRED TO ADDRESS.
>> I WILL GUESS MAYBE JUST A
LITTLE FEEDBACK THERE SPEAKING
ALSO AS A FORMER STUDY SECTION
CHAIR.
IT MIGHT NOT BE A BAD IDEA TO
PROVIDE THROUGH SOME MECHANISMS
FEEDBACK ON SOME REVIEWS THAT
START COMING IN.
THERE IS ALWAYS THE OH, YOU
HAVEN'T INCLUDED THIS.
THAT, AGAIN, TENDS TOWARDS MORE
INFORMATION.
MORE LIKE FEEDBACK, HEY, YOU
KNOW WHAT?
YOU KNOW, YOU COULD FOCUS A
LITTLE MORE ON THE KEY CRITERIA
HERE AND NOT GET LOST IN THE
DETAILS OR THAT TYPE OF HIGHER
LEVEL FEEDBACK, I THINK, COULD
POTENTIALLY BE REALLY HELPFUL,
PARTICULARLY TO EITHER YOUNG
REVIEWERS OR THOSE SET IN THEIR
WAYS, I GUESS.
>> GREAT IMPORTANCE. WE WILL
TAKE IT INTO CONSIDERATION.
>> THANK YOU AND JOYCE AND
[INDISCERNIBLE].
>> THANK YOU FOR THAT.
IT IS NICE TO SEE THAT SOME OF
THE QUESTIONS ARE COMING OUT
FROM THE TECHNICAL REVIEWER SIDE
AND BEING HANDLED BY THE -- BY
THE SCIENTIFIC REVIEW BOARD.
I GUESS THE QUESTION KIND OF
LIKE A FOLLOWUP WHAT DR. CHERRY
WAS ASKING BECAUSE SINCE NOW THE
IDEA ABOUT INVESTIGATOR AND
ENVIRONMENT IS COMING BACK TO
YOU GUYS EFFECTIVELY, DO YOU --
HAS THE THOUGHT PROCESS ABOUT
HOW TO EVALUATE THAT CHANGED?
I THINK ABOUT IT IN TERMS OF YOU
KNOW PROVIDING OPPORTUNITIES FOR
REALLY NOVEL IDEAS THAT MIGHT
NOT BE, YOU KNOW, TRADITIONAL
STATUS QUO OR YOUNG
INVESTIGATORS WHO, YOU KNOW,
MIGHT NOT BE KNOWN OR
INVESTIGATORS THAT PERHAPS HAVE
NOT MADE NAMES FOR THEMSELVES IN
THAT PARTICULAR FIELD AND
PARTICULAR STUDY SECTION AND
STILL HAVE REALLY GREAT IDEAS
THAT MIGHT BE PURSUED AND
THINKING ABOUT HOW NSF OFTEN
DEALS WITH PROPOSALS THAT GET
EITHER A VERY STRONG POSITIVE
REVIEW FROM ONE REVIEWER AND
VERY STRONG NEGATIVE REVIEW FROM
ANOTHER REVIEWER ARE USUALLY
ONES THEY BRING IN AND REALLY
THINK ABOUT, YOU KNOW, IS THIS A
NEW OPPORTUNITY TO, YOU KNOW,
REALLY FUND SOMETHING THAT IS
UNIQUE AND INDIVIDUAL
[INDISCERNIBLE] AND SPECIAL
CAPABILITY.
>> MAKING SURE THAT
INVESTIGATORS AND ENVIRONMENTS
STILL WILL BE REVIEWED BY
REVIEWER AND WILL NOT RECEIVE A
SEPARATE SCORE AND TO
DEEMPHASIZE FAMOUS AND PEOPLE
WILL FUND THE INSTITUTIONS AND
EVERY CHANGE HAS THE OFFICE
EVALUATION AND EVERY CHANGE THEY
GO BACK AND THEY COLLECT
INFORMATION AND DATA FROM
FEEDBACK FROM STUDY SECTION
MEMBERS AS WELL.
SO, THERE IS MIKE WHO I HAVE A
LINK THAT IS INCLUDED AND PUBLIC
-- THAT IS FEEDBACK TO HIGHER
UPS AND THEY READ AND LISTEN.
>> YES. THANK YOU VERY MUCH FOR
DESCRIBING AND ALL OF THE HARD
WORK THAT WENT INTO THIS.
I GUESS I HAVE A FOLLOW-UP
QUESTION TO WHAT DAN AND ANNE --
IT IS MORE KIND OF THE FIRST
QUESTION OF SHOULD PROPOSED
RESEARCH PROJECT BE CONDUCTED.
DEVIL IS IN THE DETAILS.
HOW DO YOU RECOMMEND GETTING
SUBJECTIVE OUT OF THAT?
SOMEBODY MIGHT SAY THAT IS NOT
WORTH FUNDING AND DO YOU
RECOMMEND TO THE GRANT WRITER
THAT THEY USED EVIDENCE THAT IS
ALIGNED WITH CERTAIN ICS OR I
GUESS WHAT ARE YOUR THOUGHTS ON
THAT?
THAT IS REALLY QUITE SUBJECTIVE,
I GUESS. AND MORE KIND OF
INSTRUCTION THAT YOU CAN GIVE TO
PEOPLE SO THEY UNDERSTAND SO
THEY ARE NOT JUST MAKING UP
CRITERIA FOR THAT.
>> RIGHT.
>> I UNDERSTAND HOW PROPOSED
RESEARCH PROJECT COULD BE
CONDUCTED AND PEOPLE ARE TALKING
ABOUT METHODS AND PEOPLE CAN
AGREE ON THAT.
THE MORE KIND OF IS IT WORTH
FUNDING THAT TO ME SEEMS VERY
OPEN AND VAGUE.
>> YEAH. SO, WE WILL ALLOW
PEOPLE REVIEWERS TO TALK ABOUT
FUNDING.
IT IS YOUR DECISION.
BUT YEAH. THAT IS -- THAT IS
WHY IT IS VERY IMPORTANT TO
FOCUS WHEN SHOULD THIS BE DONE
BECAUSE YOU HAVE TO EVALUATE IS
THERE SIGNIFICANCE AND THE
RESULTS OF OUTCOMES WOULD BE
SIGNIFICANT.
IS THIS INNOVATIVE AND SOMETHING
DONE BEFORE OR REPETITION OR IS
IT SOMETHING NEW?
INNOVA
INNOVATION WE TRAIN AND REMIND
THEM INNOVATION IS NOT
PARTICULARLY DOING SOMETHING NEW
AND IF YOU HAVE -- HAVE
SOMETHING AND APPLY TO NEW
QUESTIONS WILL YOU HAVE NEW
OUTCOME THAT WILL BE CONSIDERED
INNOVATION AND IS ALWAYS A
STRUGGLE DEPENDING ON OBJECTIVE
AND SOME PEOPLE SIGNIFICANT AND
SOME NOT.
SO WE ALWAYS TELL YOU THERE
SHOULDN'T BE A CONSENSUS.
SO, IF THERE IS A DISAGREEMENT
IN [INDISCERNIBLE] IT WILL BE
DISCUSSED AND BE REFLECTED IN
SUMMARY STATEMENT AND IN PROGRAM
OFFICE
OFFICERS SITTING AND LISTENING
AND THERE WILL BE PROGRAM STUFF
AND YOU DECIDE ABOUT DECISIONS
TO [INDISCERNIBLE].
>> THANK YOU. KATHY.
>> THANK YOU. I AGREE. THANK
YOU FOR ALL OF THE WORK TO PUT
THIS TOGETHER.
THESE ARE EXCITING CHANGES THAT
SHOULD MAKE THE REVIEW PROCESS,
I THINK, BETTER.
MY QUESTION IS TIED AROUND THAT
AND FUND QUESTIONS FROM EARLIER,
IS THERE AN EFFORT OR INTEREST
IN QUANTIFYING YOU HAVE GOALS
THAT MOTIVATED THIS CHANGE.
IS THERE GOING TO BE ANY
ANALYSIS OF QUANTITATIVE
ANALYSIS DID SOMETHING CHANGE?
DID YOU ACHIEVE GOALS YOU WERE
AFTER BY MAKING CHANGES?
WOULD IT BE PUBLISHED AND
AVAILABLE?
>> AS I SAID, CSR HAS AN OFFICE
OF EVALUATION.
THEY ARE -- THEY WILL BE DOING
IT AND AFTER A FEW YEARS TO
COLLECT DATA AND IN TERMS OF
PUBLICATION I HOPE THEY WILL
SHARE WITH US AND TELL US IF
THIS IS PUBLIC INFORMATION WE
CAN SHARE WITH YOU.
>> THANK YOU. ALTHOUGH SHE
CAN'T.
>> HELLO.
>> PUT HER.
>> I WILL PUT HER WHAT DO YOU
CALL IT, LINK? FOR HER
QUESTIONS.
>> RIGHT. I DID. THANK YOU FOR
GIVING THIS PRESENTATION AND
WORK YOU ARE DOING AND LOOKING
AT EVALUATION CRITERIA. MY
QUESTION IS ABOUT THE
FELLOWSHIPS.
PARTICULARLY, REALLY AROUND THE
CANDIDATE PREPAREDNESS AND
POTENTIAL.
I THINK THAT THIS IS SOMETHING
THAT THERE HAS BEEN TALK AROUND
WHAT DOES THAT ACTUALLY MEAN?
HOW DO WE GET AT, I WOULD SAY,
RIGHT, POTENTIAL, PERHAPS, MORE
THAN SORT OF THE NUMERICAL
METRICS OFTEN ASSOCIATED WITH
PREPAREDNESS AND WONDERED HOW
YOU ARE THINKING ABOUT THAT OR
WHAT GUIDANCE WOULD BE GIVEN TO
REVIEWERS AROUND PARTICULARLY
FELLOWSHIP APPLICATIONS.
>> YEAH. THE -- THAT IS A GOOD
POINT.
SO I -- WHATEVER I TOLD YOU, IT
WAS LIKE A BIG OVERVIEW.
THE MORE DETAILS ARE IN -- ON
THE WEB PAGE AND ARE COMING AND
ONE OF THE -- AS YOU SAID,
QUANTITATIVE QUALITATIVE
EDUCATION AND IN ONE CHANGE WILL
BE THAT THE -- THE GRIDS WILL BE
REMOVED.
>> YEAH. EXACTLY.
>> SO THEY WILL NOT BE -- YEAH.
>> THAT WILL BE ONE THING THAT
WILL HOPEFULLY HELP. AGAIN, THE
GOAL IS TO DEFAMIZE ENVIRONMENT
AND EMPHASIZE SPONSORS AND
CONSIDER WHAT HAS HAPPENED
BEFORE AND SOMEBODY MIGHT HAVE
SOMETHING IN THEIR LIFE AND
PARTICULARLY FOCUSING ON
PRESENTED RESEARCH TRAINING PLAN
FOR CANDIDATE AND TRAINING PLAN
AND NO THE THAT IS SOMETHING
THAT SOMEBODY KNOWS AND WHATEVER
IS PRESENTED FOR THIS PARTICULAR
CANDIDATE.
>> THANK YOU.
>> >> THANK YOU, CYNTHIA. JILL
IS REMINDING ME THAT DATA WAS
PUBLISHED, THE REDACTION.
WE WILL GET IT TO YOU.
PART OF IT WAS HARD TO
SUCCESSFULLY REDACT. CYNTHIA?
>> THANK YOU FOR YOUR WORK ON
THIS REALLY IMPORTANT
INITIATIVE.
I WAS WONDERING IF YOU HAVE
STRATEGY ON A KIND OF DIFFICULT
PROBLEM SOMETIMES DURING REVIEW,
REVIEWERS DISCUSSION AND
BRINGING UP THE DISCUSSION THAT
GOES KIND OF ON A DIRECTION THAT
WASN'T IN THE ORIGINAL REVIEW
DOCUMENTS.
AND THE SCORE CHANGES
CONSIDERABLY AND REVIEWERS ARE
ASKED TO -- I DON'T HEAR YOU.
CAN YOU SPEAK INTO --
>> I'M SORRY REVIEWERS
DISCUSSION CHANGES AND SCORES
CHANGE DRAMATICALLY FROM INITIAL
SCORES AND REVIEWERS ARE ASKED
TO GO CHANGE THEIR WRITTEN
COMMENTS.
IT DOESN'T ALWAYS HAPPEN.
THEN YOU HAVE A SCORE AND REVIEW
AND WRITTEN REVIEWS THAT CARRY
DISCREPANCY.
DO YOU HAVE STRATEGIES HOW TO
ADDRESS THAT?
>> I AM DIRECTOR OF NIBIB.
I DO HAVE STRATEGIES.
WHEN WE READ AND I SEE THERE IS
SOMEBODY THAT GIVES SCORE EVEN 3
AND NO WEAKNESSES, PLEASE GIVE
US WHAT IS THE REASON AND WHY 3
IS -- 3 AND THERE IS -- AND YOU
ARE UNHAPPY AND YOU ARE
UNSATISFIED AND WHERE IS THE
WEAKNESSES?
I WILL TELL REVIEWERS TO IMAGINE
YOU ARE IN -- YOU RECEIVE A
SCORE AND YOU ARE NOT SUCCESSFUL
AND HOW ARE YOU GOING TO ADDRESS
AND HOW WILL YOU FIX THIS IF YOU
DON'T GIVE -- YOU ARE NOT GIVEN
FEEDBACK?
SO WE DO HAVE STRATEGIES.
I CANNOT ANSWER FOR SATISFACTION
AND WHEN SOMEBODY BRINGS
ATTENTION TO THEM, THEY SAY WE
HAVE LOTS OF APPLICATIONS AND
CAN'T UPLOAD -- YOU KNOW, REACH
OUT TO EVERY REVIEWER.
SO, THAT IS IT.
I CAN'T DO THAT FOR THEM BUT WE
HAVE STRATEGY AND WE -- YOU
WON'T SEE IN OUR SUMMARY
STATEMENT.
>> THANK YOU. WE WILL CONCLUDE
THEN WITH THE QUESTIONS.
THANK YOU, MAN ANA.
>> THANK YOU.
>> AND COUNCIL MEMBERS FOR YOUR
EXCELLENT QUESTIONS.
>> AUDIENCE: [APPLAUSE].
>> AT THIS TIME WE ARE SCHEDULED
FOR A BREAK.
LET'S BREAK FOR 30 MINUTES AS
PLANNED AND RECONVENE AT 11:30.
THANK YOU!
THE RIGHT ONE. ALL RIGHT.
>> AUDIENCE: [APPLAUSE].
>> THIS ONE IS PARTICULARLY
DIFFICULT FOR ME. I BELIEVE
GILDA AND I HAVE BEEN ON SOME
KIND OF COUNCIL OR ADVISORY
BOARD FOR MAYBE LIKE 10 YEARS IN
A ROW, SO, YOU ARE ALWAYS ON
CALL TO COUNCIL. GILDA
HARABINO.
>> AUDIENCE: [APPLAUSE].
>> OH, I'M GETTING -- I WANT TO
MENTION, BRUCE, OWL TRADITION IS
TO SAY GOOD-BYE AT MAY COUNCIL
DEPARTING MEMBERS KINDLY AGREED
TO CONTINUE SHOULD THE NEXT
CLASS BE NOT APPOINTED IN TIME.
IT SEEMS TO BE A TRADITION.
THANK YOU.
>> NO.
>> THANK YOU SO MUCH.
>> AUDIENCE: [LAUGHING].
>> THERE IS A MYSTERY TO THAT
PROCESS THAT NONE OF US TRULY
UNDERSTAND. WE KNOW IT IS
ALWAYS THE WAY.
STICKING WITH THAT, WE WILL SEE
YOU AT NEXT COUNCIL.
THANK YOU SO MUCH.
NOW IS A GREAT TIME, ALSO, FOR
ME TO WELCOME NEW NIBIB STAFF.
YOU KNOW, OUR NEW STAFF IS JUST
INCREDIBLE.
THEY ARE -- THEY ARE REFLECTIVE
OF EXCELLENCE OF OUR EXISTING
STAFF. I WILL GO THROUGH EACH
ONE VERY BRIEFLY.
IF YOU COULD JUST STAND AND WAVE
AND, YOU KNOW, WE WILL THANK YOU
FOR COMING ON BOARD.
MARTIN, I WILL SAY A FEW WORDS
ABOUT EVERYONE BRIEFLY.
MARTIN?
MAR CONTINUE WAS PREVIOUSLY
ASSOCIATE PROFESSOR OF
BIOMEDICAL ENGINEERING AT DUKE
AND HAS ALL EXPERIENCE IN
IMAGING INTERSECTING WITH MARTIN
OVER COURSE OF OUR YEARS IF YOU
HAVE BEEN IN IMAGING HE DOES
NUCLEAR AND X-RAY-BASED IMAGING
AND PET RI AND COMBINATION AND
IN COMBINED MODALITIES AND IS AN
ENTREPRENEUR AND START-UP IN CT
IMAGING AND BREAST CANCER AND
ONE AREA OF EXPERTISE AND MARTIN
TRAINED WITH JERRY IN THE UCLA
DAYS AT CRUMP INSTITUTE THAT I
HAD A CHANCE TO VISIT A FEW
TIMES.
WELCOME. WE ARE SO GLAD TO HAVE
YOU.
>> AUDIENCE: [APPLAUSE].
>> NEXT PERSON I WOULD LIKE TO
INTRODUCE TODAY IS
[INDISCERNIBLE] A GRANTS
SPECIALIST IN OFFICE OF GRANTS
MANAGEMENT WHO HAS ENORMOUS
LEADERSHIP AND EXPERTISE IN THAT
AREA THAT WAS BUILT BEING A
SUPERVISOR TEAM LEAD AT NCI AND
SHE MANAGED AN OPERATION THAT
INCLUDED THINGS LIKE NCI'S
CANCER MOONSHOT AND PROGRAMS
RELATED TO THAT AND PRIOR THAT A
LEAD GRANT SPECIALIST AT NYA.
HER EDUCATION IS REALLY
IMPRESSIVE.
SHE HAS BACKGROUND WITH A
BACHELORS IN BEHAVIORAL SOCIAL
SCIENCE FROM UNIVERSITY OF
MARYLAND AND MASTERS IN PUBLIC
ADMINISTRATION FROM GEORGE
MASON.
SHE HAS ALSO COMPLETED MID-LEVEL
NIH EXECUTIVE TRAINING PROGRAM.
WELCOME.
>> AUDIENCE: [APPLAUSE].
>> JENNA HARRISON PETERS, IS
JENNA HERE?
>> I DON'T THINK SO.
>> POSSIBLY IN THE OTHER ROOM?
OKAY. BUT.
>> ZOOM.
>> SHE IS ON ZOOM, TERRIFIC.
JENNA, IF ON ZOOM, STAND UP.
>> SHE IS ON.
>> JENNA HAS TAKEN ON POSITION
AS GRANT MANAGEMENT SPECIALIST
AND AGAIN OFFICE OF GRANTS
MANAGEMENT.
SHE HAD A POSITION THAT WAS
SIMILAR TO THIS FOR TWO YEARS AT
NIAD THAT I UNDERSKO R --
UNDERSCORE IS SECOND OR BIGGEST
DEPENDING HOW YOU COUNT NIH
INSTITUTES AND IS CONCENTRATED
IN A MORE I GUESS LESS
WELL-FUNDED BUT VERY COHERENT
AND COLLABORATIVE INSTITUTE. WE
ARE SO GLAD TO HAVE HER ON
BOARD.
SHE BRINGS A REALLY INTERESTING
BACKGROUND.
HER MASTERS IS IN PUBLIC HEALTH
AND EPIDEMIOLOGY FROM THE
UNIVERSITY OF MARYLAND.
SHE HAS BEEN A PATHWAY'S INTERN
AT NIHNIAD.
LET'S WELCOME JENNA.
FINALLY, JOSH.
WILL YOU HAVE TO HELP ME WITH
YOUR LAST NAME.
OKAY. IT IS JUST LIKE IT IS
SPELLED.
IT IS REALLY EASY.
HE IS A GRANTS MANAGEMENT
SPECIALIST AT NIBIB. YOU SHOULD
BE HAPPY WE ARE HIRING GRANTS
MANAGEMENT SPECIALISTS.
THIS IS A GOOD SIGN.
THEY ARE SO EXPERIENCED AND
TALENTED AND STARTED FEDERAL
CAREER AT NIH AT NIAD IN 2020.
HE HAD PRIOR GOVERNMENT
EXPERIENCE IN DEPARTMENT OF
HOMELAND SECURITY AND THAT IS
ALWAYS A REALLY INTERESTING
PLACE TO WORK AND I'M LOOKING
FORWARD TO HEARING STORIES ABOUT
THAT WHERE HE WAS A TEAM LEAD
AND FINANCIAL ANALYST AND AGAIN
REALLY INCREDIBLE TRAINING.
WAS AN UNDERGRADUATE AT
UNIVERSITY OF MARYLAND AND
BACHELOR BS IS IN COMPUTER
INFORMATION TECHNOLOGY AND
GRADUATE EDUCATION AN MBA FROM
UNIVERSITY OF MARYLAND AND SO
GLAD TO WELCOME YOU HERE AND
BRING THAT EXPERTISE TO OUR
COMMUN
COMMUNITY.
IN THE BUILD, I DON'T HAVE ROOM
FOR ALL OF THE PICTURES OF ALL
OUR CORE, OUR STAFF AND EVERYONE
INVOLVED IN ALL OF OUR DIFFERENT
OFFICES.
THIS IS TO REMIND YOU THAT WHEN
YOU HAVE FOUR MAJOR DIVISIONS I
WAS MYSTIFIED BY STRUCTURE AND
WHERE IS EVERYBODY GOING AND HOW
ARE ALL OF THE OFFICES AND
GROUPS THAT ARE INTERCONNECTED
AND OFFICE OF RESEARCH AND
ADMINISTRATION AND OFFICE OF
ADMINISTRATIVE MANAGEMENT AND
EXTRAMURAL PROGRAM AND
INTRAMURAL RESEARCH PROGRAM.
THANKS TO ALL OF YOU. I WON'T
MAKE YOU ALL STAND BUT LET'S
GIVE A ROUND OF APPLAUSE FOR OUR
COMMUNITY.
ONE ANNOUNCEMENT THAT PROBABLY
EVERYONE SAW AND I DO WANT TO
REALLY RE-ENFORCE THE
CONGRATULATIONS HERE.
OUR COUNCIL MEMBER WAS ELECTED
IN THIS RECENT CLASS TO NATIONAL
ACADEMY OF ENGINEERING AND BROWN
DEAN OF ENGINEERING AND NIBIB
COUNCIL MEMBER. HER CITATION
FOR HER ELECTION AND
DISTINGUISHED CONTRIBUTIONS TO
ENGINEERING OR NANOFABRICATED
MATERIALS TO CONTROL BIOLOGICS
DELIVERY AND LEADERSHIP IN FIELD
OF [INDISCERNIBLE].
CONGRATULATIONS.
>> THANK YOU. SORRY I COULDN'T
BE THERE. I MISS YOU ALL.
>> WE DO MISS YOU AND HOPE TO
SEE YOU IN SEPTEMBER.
>> ABSOLUTELY.
>> YEAH.
>> MULTIPLE PLACES, EXACTLY.
>> YEAH. YEAH.
SO JUST TO -- EVERYONE, OF
COURSE, IS FAMILIAR WITH THE
FINAL PASSING OF THE FEDERAL
BUDGET.
AND JUST A FEW POINTS TO
HIGHLIGHT.
OF COURSE, THERE WAS EFFECTIVELY
NO CHANGE AND ACROSS THE FEDERAL
BUDGET, NO CHANGE WITH NIBIB
BUDGET.
WE HAD TO SPEND ALL OF THAT TIME
THEN FIGURING OUT HOW TO LOCK IN
ON THE PAY LINE.
PAY LINE FOR THE PARENT RO1S,
JUST TO RE-ENFORCE THIS, I THINK
THAT MANY OF YOU MAY KNOW
ALREADY THAT IT IS 16
PERCENTILE.
THIS INCREASES WITH NEW
INVESTIGATORS THIS YEAR ONLY TO
21 PERCENTILE AND 29 PERCENTILE
FOR EARLY-STAGE INVESTIGATORS
THAT IS, AGAIN, THIS YEAR ONLY.
THESE PAY LINES ARE REALLY
STRUCTURED IN ORDER TO SORT OF
DRIVE TWO MAJOR PHILOSOPHICAL
POINTS.
WE WANT TO SUSTAIN COMPETING
RO1S ABOUT SAME LEVEL THEY HAVE
BEEN OVER SEVERAL YEARS NOW.
ULTIMATELY WHEN WE ANNOUNCE
FINAL NUMBERS OF R01S WE ARE
CONFIDENT THEY WILL BE ABOUT THE
SAME IF THEY WERE LAST YEAR AND
PREVIOUS YEAR AND DIDN'T WANT TO
JEOPARDIZE THAT.
SECOND, SOMETHING THAT HAS BEEN
OBSERVED ACROSS THE NIH AS
FUNDING LEVELS ARE MORE
DIFFICULT TO GET AND DRAW EARLY
STAGE INVESTIGATORS TEND TO
SUFFER THE MOST.
WE WANT TO CONSERVE GRANTS
ISSUED TO ESIS AND WHY WE WENT
UP TO 29TH PERCENTILE FOR ESIS
AND ONLY THIS YEAR AND
REFLECTING THE FACT THAT THESE
NUMBERS ARE NOT WRITTEN IN STONE
BUT DESIGNED TO HELP SUPPORT
WHAT WE BELIEVE FROM YOUR
FEEDBACK AND INTERACTING WITH
THE COMMUNITY AND WHAT THE
COMMUNITY NEEDS THE MOST.
TO KIND OF DO THAT, YOU KNOW,
THIS IS A CONSERVATION OF ENERGY
CONSERVATION AND MASS PROBLEM.
WE HAD TO MAKE ADMINISTRATIVE
CUTS.
THE ADMINISTRATIVE CUTS WE
INVOKED RUN LIKE PRIOR YEARS IN
BUDGET TIMES AND YOU WILL SEE
PRECEDENT FOR THESE AND ALSO
FROM OTHER INSTITUTES.
SO THAT IS 24% TO R01S THAT WILL
GO TO NON-ESIS WITH NON-MODULAR
BUDGETS THAT IS KIND OF SOMEWHAT
CODE LANGUAGE FOR LARGEST BUDGET
R01S FROM MOST EXPERIENCE AND
SUCCESSFUL INVESTIGATORS AND 15%
TO U0 ONES THAT ARE
BIOENGINEERING PARTNERSHIPS WITH
INDUSTRY AND BPI AWARDS AND 10%
TO K4 ONES IN FIRST YEAR ONLY
AND SUBSEQUENT YEARS THAT CUT
DISAPPEARS AND 10% TO R2 ONES
THAT ARE IN THE PARENT.
SO THAT WOULD NOT BE TO THE
TRAILBLAZER AWARD AND ONLY
PARENT R2 ONES.
AS OTHER ICS ARE DOING, IN ORDER
TO CREATE ROOM IN THE BUDGET AND
BULK OF RESEARCH BUDGET IS
SOMEWHERE AROUND 2/3 OR SO GOES
TO COMPETING AWARDS.
SMALL REDUCTION, 2% IN COMPETING
R01S AND OTHER ICS FOR
COMPARISON IN 3 TO 5% AND RAIN
INITIATIVE AS I THINK MANY OF
YOU HAVE FOLLOWED THE 2 FIRST
CENTURY CARES ACT REDUCTION OR
LACK OF SUPPORT IN THIS CURRENT
YEAR.
IT IS A 10% REDUCTION IN THOSE
COMPETING R01S THAT HAS HELPED
US MAINTAIN PAY LINE AND R01S AS
WE HOPED AND ENORMOUS AMOUNT OF
WORK. THANK YOU SO MUCH TO OUR
BUDGET OFFICE AND LEADERSHIP
TEAM OF DAVID AND JILL.
WE APPRECIATE MODELING THAT YOU
HAVE DONE THAT IS REALLY
TRANSFORMATIONAL FOR US AND
ALLOWS US TO MAKE THESE
DECISIONS.
ON THAT NOTE, I MEAN, THIS
REALLY ILLUSTRATES THE STARK
REALITY OF WHAT HAS HAPPENED
WITH 21ST CENTURY CURES FUNDING.
YOU HAVE SEEN THAT ENACTED
BUDGET FOR BRAIN INITIATIVE IS
SIGNIFICANTLY LOWER THAN WHAT
HAD BEEN ENACTED IN THE PREVIOUS
YEAR.
AND IF YOU SPEAK WITH JOHN WHO
IS HEAD OF THE INITIATIVE AND
HAS BIN CREDIBLY CREATIVE AND
VERY, VERY BUSY AND TRYING TO
FIGURE OUT HOW TO PRIORITIZE AND
RANK APPLICATIONS TO BRING AND
HOW TO I THINK CREATIVELY BRING
IN NEW RESOURCES FROM OTHER
INSTITUTES AND FROM ALL OF THE
BRAIN INSTITUTES TO MAKE UP SOME
OF THAT SIGNIFICANT SHORTFALL IN
BRAIN AND PIVOTING OPTIMISTIC
FUNDING OPPORTUNITIES WHERE WE
KNOW FUNDING WILL BE ISSUED.
FIRST ONE, OF COURSE, TYING INTO
DR. CLAYTON'S INCREDIBLE
PRESENTATION THIS MORNING, WE
THINK IT WILL BE AN EXPANDING
SET OF RESOURCES AND AN ENORMOUS
AMOUNT OF INTEREST GENERATED IN
WOMEN'S HEALTH OPPORTUNITIES AS
JANINE TALKED ABOUT WOMEN'S
EXECUTIVE ORDER FROM PRESIDENT
BIDEN CAME IN MARCH THIS YEAR
AND IS A PHOTO THAT DR. CLAYTON
ALSO SHOWED WITH HER MONICA BER
TAN OELI NIH DIRECTOR AND TARA A
DEBUTY DIRECTOR OF NIH WHO IS IN
THAT PICTURE AS WELL AND RENÉ
FROM ARPAH AND NIBIB IS SIGNED
ON TO ALL NWH LED OPPORTUNITIES
NOT JUST IN RESEARCH BUT IN
TRAINING AND CAREER ADVANCEMENT
AND RECOMMEND THAT YOU TAKE A
LOOK AT THESE.
CONTACT TINA ON THE FIRST ROW
AND PEOPLE SHOULD CONNECT WITH
HER AND DAVID.
IF YOU HAVE QUESTIONS, HE IS
NEXT DOOR.
TINA IS POINTING OVER THERE.
WE ARE HOPEFUL TO BE AT THE
CENTER PART OF THE DRIVING FORCE
OF FUNDING AND PROMOTING SEVERAL
OF THESE OPPORTUNITIES.
JANINE MENTIONED THE ACT ENDO
CHALLENGE THAT IS HOT. SHE
DIDN'T KNOW IT HERSELF AND I
CENTERED THESE TWO SLIDES.
AS MANY OF YOU KNOW, WE HAVE A
STRONG PARTNERSHIP WITH NIH AND
NICHD ON MANY DIFFERENT AREAS
AND ONE IS IN THE RAD X TECH FOR
MATERNAL HEALTH AND WE PARTNER
WITH THEM AND ORWH.
SO NICHD, WHEN THEY HAD TO
REALLY THINK ABOUT HOW TO PULL
OFF A FAST, EFFECTIVE AND
IMPACTFUL PROGRAM, THEY HAD
ANNOUNCED ALREADY THE PROGRAM
BUT HADN'T REALLY SETTLED ON A
FUNDING MECHANISM.
THEY HAVE NOW RESOLVED THAT.
THEY WILL DO SOMETHING VERY S
SIMILAR TO IT CH.
>> LONGER TIME SPANS REALLY
PIONEERED BY NIA THAT OF COURSE
IS INTERESTED IN TIME BOTH
FORWARD AND REVERSE HOPEFULLY
PROGRESS
PROGRESSIONS.
YOU CAN CONTACT COLLEAGUES ON
THIS THIS IS DEVELOPMENT AND AIM
IN HYPOTHESIS TESTING AND SOME
CONSTRAINTS THIS IS AN
INTERESTING ONE.
I'M REALLY CURIOUS, INCLUDING
TWO TIME POINTS MEANINGFULLY
SEPARATED IN TIME.
HOW CAN YOU BANK THE MONEY AND
PULL IT OUT WHEN YOUR SUBJECT
ENTERS MIDDLE AGE WHEN YOU START
THE STUDY WHEN THEY ARE LET'S
SAY A TEENAGER OR SOMETHING LIKE
THAT.
HOW DOES THIS WORK?
>> TO HAVE A COMPARISON OF
DIFFERENT LIFE POINT AND
LONGITUDINALLY AND MEASURING
THEM.
I THINK THAT, YOU KNOW, BECAUSE
IT IS A SORT OF -- THERE IS A
FIRST STEP OF COMPREHENSIVE
EFFORTS THAT QUITE A NUMBER OF
INSTITUTES HAVE BEEN THINKING
ABOUT.
AT THIS POINT, I THINK IT IS,
YOU KNOW, INSTEAD OF HAVING
POINTS THAT I THINK WILL ANSWER
SORT OF INITIAL STEPS AND WE ARE
THINKING OF HAVING TWO POINTS
AND COMPARING THEM.
REALLY, TO ENCOURAGE THE
COMMUNITY TO THINK ABOUT THE
LIFESPAN AND RESEARCH AND ISSUES
INSTEAD OF LOOKING AT
[INDISCERNIBLE] POINTS.
>> YEAH, YEAH.
>> YEAH.
>> SO THERE IS -- YEAH.
>> THERE IS A LOT THAT NEEDS TO
BE WORKED OUT AND WE WORK REALLY
AND EXCITED TO SEE HOW THE
COMMUNITY RESPONDS TO THIS.
>> YES. THANK YOU. I MEAN,
THIS IS REALLY EXCITING.
IT IS KIND OF YOU KNOW WHEN WE
ARE TOGETHER TALKING ABOUT WHAT
ARE MOST LOGICAL WAYS TO LOOK AT
AGING AND REVERSAL, YOU KNOW, WE
WOULD LIKE TO SEE CONTINUOUS
LONGITUDINAL STUDIES WITH
APPLICATION OF VARIETY OF
DIFFERENT TECHNOLOGIES AND
APPROACHES AND PRACTICE, OF
COURSE, OF MEDICINE IS FAR FROM
THAT.
THIS IS AN EXCITING OPPORTUNITY
AND PLEASE CONNECT WITH GOYING
TO FIGURE OUT HOW WE CAN MOST
CAPITALIZE ON THAT.
THANK YOU GOYING.
NOW I HAVE A SERIES OF
SUPPLEMENTAL FUNDING
OPPORTUNITIES THAT ARE DRIVEN BY
THE OFFICE OF DATA SCIENCE AND,
OF COURSE, WE ARE SO INTIMATELY
AND STRONGLY CONNECTED WITH
THAT.
QI.
DUAN IS CONTACT PERSON FOR THIS
AND FIRST IS USE OF CLOUD
SERVICES AND CLOUD RESOURCES IN
NIH-SUPPORTED RESEARCH.
AGAIN, THESE ARE COMPETITIVE
REVISIONS TO YOUR EXISTING
AWARDS.
AND THE NIH CLOUD LAB HAS OPENED
UP.
IT IS ACTUALLY REALLY IN TRYING
TO INSPIRE SIGNIFICANT USE FROM
INTRAMURAL AND EXTRAMURAL
COMMUNITY AND YOU CAN LOOK ON
THEIR WEBSITE. I NOTICE THERE
IS A $500 CREDIT FOR ACTUALLY
SIGNING UP AND GETTING STARTED
WITH THE NIH CLOUD LAB.
OF COURSE, I'M SURE THAT IS ONE
OF THE CLASSIC ADDICTIONS YOU
GET STARTED WITH 3500 AND BEFORE
YOU KNOW IT, I WON'T COMPLETE
THE SENTENCE.
YOU KNOW WHERE I'M GOING WITH
THAT.
THIS IS A REALLY, REALLY
IMPORTANT WAY FOR OUR COMMUNITY
TO COME TOGETHER AND GIVE
FEEDBACK ON WHAT WORKS IN THE
TECHNOLOGY DEVELOPMENT SPACE.
THIS IS ONE.
A SECOND IS, AS YOU KNOW, I
THINK MORE IN THE MEDICAL
COMMUNITY.
THE BROADER MEDICAL COMMUNITY,
THERE IS A HOPE THAT AT LEAST
CERTAINLY FOR PEOPLE NOT
DEVELOPING NEW TECHNOLOGIES ALL
THE TIME.
THERE IS A HOPE THAT EXISTING
DATA AS IT BECOMES AVAILABLE CAN
BE PUT INTO A STRUCTURE AND THEN
REUSED TO DRIVE NEW DISCOVERY
ALMOST AS IF IT IS A NEW
TECHNOLOGY THAT WERE CREATED BY
OUR COMMUNITY THAT IS GENERATING
ENTIRELY NEW WAYS TO MEASURE
THINGS.
THIS IS PROBABLY THE BULK OF
THE ASPIRATIONAL GOALS OF ALL
INSTITUTES ACROSS NIH.
WE ARE SORT OF OUTLIARS SAYING
WE NEED NEW TECHNOLOGY AND
MEASUREMENTS AND WAYS TO SEE
THINGS.
WE AS A COMMUNITY HAVE TO REALLY
RESPOND TO THIS KIND OF APPROACH
TO BOTH HELP TO CONTINUE TO
PROMOTE THE ROLE OF NEW
TECHNOLOGIES BUT POWER OF DATA
REUSE.
THIS IS, AGAIN, A COMPETITIVE
REVISION TYPE OF APPLICATION.
AND I ENCOURAGE YOU TO TALK TO
QI.
AWARD SIZES ARE LIMITED AND
TOTAL AMOUNT IS $275,000 DIRECT.
BUT, UP TO 200,000 DOLLARS IN
CAP FOR ANY GIVEN YEAR.
TAKE A LOOK AT DETAILS OF THAT.
AND THEN IF YOU HAVE NOT HAD
ENOUGH OF DATA YET, HERE IS YET
ANOTHER EXCITING INITIATIVE THAT
IS LED BY OUR -- IN FACT, DID WE
GET ALL OUR DATA SCIENCE EXPERTS
HERE ON THIS SLIDE?
MO AND QI AND BRAD IF YOU COULD
STAND. BRAD IS PROBABLY IN
NOVRJ CAROLINA BUT YEAH. SO
PLEASE CONNECT WITH THEM.
THIS IS A REALLY EXCITING
INITIATIVE AND MULTIMODAL AI IS
KIND OF OUR NATURAL SET POINT IN
OUR COMMUNITY WHETHER YOU ARE
USING A COMBINATION OF
APPROACHES WHERE, YOU KNOW, YOU
ARE KIND OF THE BASIS OF A
PHYSICS MODEL OR SIM BIOLOGIC
TROOPS TO DO MECHANISTIC AI
BASED APPROACHES OR USING
MULTIPLE MODALITIES WITHIN AI
ITSELF AND COMBINATIONS OF
DIFFERENT LEARNING PROCESS.
THAT IS WHAT WE DO.
I THINK THAT THE BROADER
COMMUNITY NEEDS TO REALLY SEE
POWERFUL APPROACHES AND THINK IF
YOU ARE HOPEFULLY APPLYING AND
WE ARE GETTING PRETTY GOOD
RESPONSE TO THIS.
QI, WHAT IS YOUR -- IS THAT --
>> YES. YES. THIS WILL
PROBABLY COME AROUND AGAIN.
THIS WILL PROBABLY COME AROUND
AGAIN.
IT IS -- I THINK OR YOU THINK
THIS WILL BE A ONE YEAR KIND OF
INITIATIVE? I'M PUTTING YOU ON
THE SPOT. YEAH. WITH ENORMOUS
AMOUNT OF INTEREST IN AI, SOME
OF YOU NOW THAT YOU ARE INSIDE
OF THE BELTWAY YOU ARE PROBABLY
FOLLOWING SENATOR SHOOUM AR'S AI
RECOMMENDATIONS THAT CAME OUT
YESTERDAY.
I ALONG WITH JONI AND ASSIST
YANTD DIRECTOR HAVE DONE SEVERAL
CONGRESSIONAL BRIEFINGS ON AI
AND WE HAVE ANOTHER ONE COMING
UP NEXT WEEK.
THERE IS ENORMOUS INTEREST AS
NIH AND ALTHOUGH WE ARE NOT AN
OFFICIAL FOUNDING AGENCY WITHIN
THE NATIONAL AI RESEARCH
RESOURCE, WE ARE THE GO-TO
AGENCY FOR HELP WITH BOTH
RESPECT TO NEW METHODS AND THEIR
DEVELOPMENTS AND APPLICATIONS
AND FOR ALSO GUIDELINES TO
IDENTIFY AND OPTIMIZE USE AND OF
COURSE CONGRESS IS VERY, VERY
INTERESTED IN REGULATING ITS
USE.
WE HAVE TO BE REALLY DEEPLY
ENGAGED IN THAT CONSTRUCTION FOR
THAT CONVERSATION AND THIS IS
ONE OF THOSE OPPORTUNITIES FOR
OUR COMMUNITY.
THANK YOU, YOU GUYS.
SO ANOTHER ADMINISTRATIVE
SUPPLEMENT OPPORTUNITY THAT WE
HAVE I THINK BEEN FORESHADOWING
THIS FOR A WHILE.
WE HAVE OUR IMAGING PHANTOM
LIBRARY AND OUR LENDING LIBRARY
THAT WE HAVE EXPANDED THAT TO
INCLUDE SOME OPTICAL
TECHNOLOGIES INCLUDING OPTICAL
[INDISCERNIBLE] AND SXABDING
COLLABORATIONS THERE.
THIS IS ADMINISTRATIVE
SUPPLEMENT THAT SUPPORTS
OPTIMIZATION, CALIBRATION,
DISSEMINATION OF IMAGING
PHANTOMS AS PART OF YOUR PARENT
AWARD.
THIS IS DESIGNED TO REALLY
IMPROVE QUALITY ASSURANCE AND
PERFORMANCE DURING TECHNICAL
DEVELOPMENT DURING IMAGING
TECHNOLOGIES AS WELL AS TO TRY
TO ACCELERATE DATA SHARING AND
REGULATORY CLEARANCES.
WE THINK, YOU KNOW, THESE ARE --
THEY CLEARLY PLAY A VERY
IMPORTANT ROLE AND IS AN
OPPORTUNITY TO REALLY ADVANCE
[INDISCERNIBLE] AND ANDERSON IS
THE LEAD ON THIS ONE.
SO HOPEFULLY MANY OF YOU HAVE
TALKED TO HER ABOUT THIS AND
WILL BE ABLE TO RESPOND TO THIS
INITIATIVE.
SO IT IS ACTUALLY SURPRISING
THAT THIS IS -- NOW WE ARE
ANNOUNCING THE REAPPEARANCE OF
THE BETA, THE BEI AND BIOMEDICAL
IMAGING TECHNOLOGY ACCELERATION
INITIATIVE AT HBCU AND HAD FIRST
ROUND OF APPLICATION END OF
JANUARY AND THEY ARE NOW IN
REVIEW.
BY THE TIME THAT THESE
APPLICATIONS ARE DUE WHEN WE
UPDATE YOU IN THE -- IN COUNCIL
IN SEPTEMBER AND HOPEFULLY WILL
BE ABLE TO ANNOUNCE WINNERS OF
THAT FIRST ROUND AND A SECOND
OPPORTUNITY IS NOW COMING UP.
THESE DUE DATES ARE AT THE END
OF SEPTEMBER THIS YEAR AND END
OF SEPTEMBER THE FOLLOWING YEAR
AND THAT WILL HAVE BEEN THREE
FULL APPLICATION DUE DATES FOR
THIS AWARD AND ARE EXCITED TO
SEE OUTCOMES ENCOURAGING PEOPLE
TO APPLY FOR THIS AND IT IS
AWARD UG3UH3 IN TERMS OF PHASE 2
AND ALBERT ALVILLA IS OUR
CONTACT FOR THAT.
NOW, A FEW PROGRAM UPDATES.
WE HAD A SPECTACULAR WORKSHOP
AND IF YOU CAN DO A Q.R. CODE
AND SCAN FROM YOUR REMOTE
LOCATION WE WILL HAVE PDF SLIDE
THAT WE WILL UPLOAD THAT YOU CAN
GET ACCESS TO AND TALKED IN THE
MIDRC SESSION THAT ARE AMONGST
BEST TALKS I HAVE SEEN COVERING
ISSUES AND CHALLENGES OF AI.
NOT JUST TECHNICAL ONES BUT KIND
OF THE BROAD OVERVIEW OF HOW YOU
STRUCTURE MULTIPLE DATABASES IN
A CONNECT THE NETWORK AND DATA
FABRIC SO-TO-SPEAK THAT SPANS
ACROSS MULTIPLE DOMAINS.
THIS IS NOW AVAILABLE TO THE
PUBLIC AND NOW ON MIDRC WEBSITE.
IT WAS A VERY, VERY PRODUCTIVE
MEETING AND QUICK UPDATES ON
MIDRC.
WE TALKED ABOUT HOW MIDRC ITSELF
IS PART OF ARPA H'S DATA FABRIC
AND HAD A NUMBER OF SPECIFIC
GOALS AND DELIVERABLES THAT IS
PART OF THAT AND SOME HIGHLIGHTS
WHAT THEY HAVE BEEN ABLE TO
ACCOMPLISH.
WE ARE I HAVE BIASED AND BELIEVE
THESE ARE MOST IMPORTANT GOALS
AND ARE DOING A REALLY GOOD JOB
OF DELIVERING ON THOSE.
IT IS A METAINDEXING OF MIDRC
INSIDE OF IMAGING DATA COMMONS
IN THIS DATA FABRIC IMAGING HUB
AND THAT SOUNDS VERY DIFFICULT
TO UNDERSTAND LANGUAGE.
IF YOU DO TAKE A LOOK AT THIS
YOUTUBE VIDEOCAST, YOU WILL KIND
OF UNDERSTAND THE IDEA OF THE
DATA BASES AND DATA FABRIC AND
DATA HUB.
THIS IS ALL HOSTED ON THE JENTRY
PLATFORM THAT HAS SOMETHING LIKE
18 SEPARATE DATA BASES THAT ARE
ON DIFFERENT TOPICS.
BECAUSE IT IS ON A SINGLE
PLATFORM, YOU ARE ACTUALLY ABLE
TO INTERCONNECT AND INTEROPERATE
BETWEEN THESE DATA RESOURCES.
WHAT IS INTERESTING FOR MIDRC IS
THEY HAVE THOUSANDS OF PATIENTS
IN COMMON WITH DATA BASES HOSTED
ON GEN3 AND DATA COMMONS AND IS
AN ENORMOUS OPPORTUNITY THAT IS
A ROADMAP FOR HOW DATA BASES
WILL EVOLVE INTO THIS KIND OF
FABRIC THAT IS ENVISIONED BY
ARPAH AND MANY OTHERS AND IS A
VERY IMPORTANT ACHIEVEMENT AND
ARE PRACTICAL TOOLS THAT MIDRC
HAS CONTRIBUTED TO THE DATA
FABRIC IS DIVERSITY CALCULATOR
THAT ALLOWS YOU TO COMPARE DATA
SETS YOU HAVE ACQUIRED WITH US
CENSUS DATA TO SEE HOW CLOSELY
YOU ARE MATCHING AND
REPRESENTING THE POPULATION IN
YOUR DATA SET.
I HAVE TALKED ABOUT THE BIAS
AWARENESS TOOLS THAT I THINK ARE
REALLY UNEQUAL.
THEY ARE DEVELOPED BY MIDRC.
THEY ARE ALL AVAILABLE ON THE
MIDRC WEBSITE AND NOW IN
BIOMEDICAL DATA FABRIC UNIVERSE,
SO-TO-SPEAK.
MIDRC DEVELOPED A TEXT
DEIDENTIFICATION TOOL THAT WORKS
BETTER OR ON PAR WITH
UNPUBLISHED ALGORITHMS AND
ULTIMATELY THE EXPECTATION IS
THAT THESE KINDS OF DATA
APPROACHES NEED TO TAKE
ADVANTAGE OF FEDERATED LEARNING
OPPORTUNITIES AND YOU NEED THE
PROPER STRUCTURE WITH EDGE NODES
THAT ARE DEVELOPED IN CONNECTION
WITH THIS FABRIC AND THINK THAT
YOU GET AN APPRECIATION FOR THIS
IF YOU LOOK AT THE VIDEO WHERE
BOB GROSSMAN PRESENTS OVERALL
CONCEPTUAL FRAMEWORK FOR THESE
ARCHITECTURES AND BOTTOM LINE IS
THAT MIDRC AND RELATED DATA
BASES ARE IN IDEAL POSITION TO
BEGIN ENGAGING AND DRIVE
FEDERATED LEARNING APPROACHES
THAT WILL DRAMATICALLY EXPAND
THE IMPACT OF DATA BASES IN
DIFFERENT SITES ALL OVER THE
COUNTRY AND POTENTIALLY HELP
PLACES GET OVER WHATEVER
POLICIES THEY MIGHT HAVE ABOUT
DATA SHARING INTO A SINGLE DATA
REPOSITORY.
LOTS OF THOUGHTFUL CONSTRUCTION
GOING ON AND LOTS OF GREAT
DIALOGUE.
LAST THING I WOULD LIKE TO SAY
ABOUT MIDRC IS THAT IT IS KIND
OF ALMOST LIKE ONE OF THE
ULTIMATE BADGES OF RECOGNITION
AND HONOR THAT IS GETTING CALLED
OUT BY THE FDA FOR DOING
SOMETHING THAT THEY WANT
EVERYBODY ELSE TO DO.
SO, MIDRC HAS THIS DECISION TREE
FOR MEDICAL IMAGING AND AI ML
CLASSIFICATION METHODS.
THE FDA HAS NOW PUBLISHED THIS
IN THEIR GUIDE FOR HOW TO DO
MEDICAL IMAGE CLASSIFICATION.
AND IT COVERS MANY DIFFERENT FDA
PRODUCT CODES.
IT IS NOT JUST COVID DIAGNOSTIC
AS MIDRC WAS DEVELOPED FOR IN
THE FIRST PLACE BUT COVERS A
VARIETY OF DIFFERENT
APPLICATIONS BASIS.
YOU CAN GO ON TO THE MIDRC
WEBSITE AND SEE THE MIDRC METRIC
TREE FOR CLASSIFICATION DETECTOR
LOCALIZATION SEGMENTATION AND
TIME FOR [INDISCERNIBLE]
ANALYSIS AND REALLY INCREDIBLE
TOOLS AND IF DOING IMAGING AT
ANY SCALE AND YOU WANT TO
SEGMENT AND CLASSIFY AND DO
ANYTHING IN A KIND OF AUTOMATED
WAY, THIS IS VERY, VERY
POWERFUL.
I ENCOURAGE EVERYONE TO TAKE A
LOOK AT THAT.
SO NOW JUST A FEW QUICK UPDATES
ABOUT RAD X.
WE ARE UP TO 8 DIFFERENT RAD X
PROJECTS THAT ARE GOING ON RIGHT
NOW AND RAD X FOR ENDOMETRIOSIS
THAT IS 8 AND CARE AND VIRAL
LOAD DIAGNOSTICS THIS IS A NEW
LOAD EFFORT WITH SUBSTANTIAL NEW
INVESTMENT LED BY SEAN MUL VAINY
WHO HAS MANAGED TO WORK VERY
CLOSELY WITH OFFICE OF AIDS
RESEARCH AND NIAD.
I WAS VERY SURPRISED TO SEE
THEIR COMMITMENT IT IS NOW A 10
MILLION DOLLAR PROGRAM THAT WILL
PROVIDE SIGNIFICANT SUPPORT TO
PERFORMERS DEVELOPING
DIAGNOSTICS AND GOAL IS TO GET
TO QUANTITATIVE TESTS AT POINT
OF CARE LESS THAN 1,000 COPIES
PER MILL AND IDEALLY LIMITS
DETECTION THAT IS 200 COPIES PER
MILL. IF A COUPLE HUNDRED
COPIES PER MILL AND ON TREATMENT
YOU ARE CONSIDERED TO BE NOT
CONTAGIOUS AND IS AN IMPORTANT
FACTOR AND DON'T KNOW HOW COPY
NUMBERS FLUCTUATE OVER TIME AND
POINT OF CARE AND OVER COUNTER
TYPES OF APPROACHES WOULD ALLOW
US TO VISUALIZE DYNAMICS OF THAT
AND DO A BETTER JOB COUPLING
TREATMENT AND DIAGNOSIS AND
PRECISION-LED DIAGNOSTICS THAT
REALLY BUILDS ON PUCK TURN
PROGRAM AND STRENGTHENS
CONNECTIONS AND MULTIPLE
SUBJECTS WILL BE LOOKED AT AT
JOHNS HOPKINS AND CLINICAL
CAPABILITY STUDIES AND
MARKETPLACE LANDSCAPE AND
ANALYSIS AND SUBJECT MATTER
EXPERTS FROM NORTHWESTERN ARE
DEEPLY ENGAGED AND ANALYTICAL
TESTING AND HOME LABS EVALUATION
THAT IS ONGOING AND RAD X
PROJECTS APP KNEE CENTER AT
[INDISCERNIBLE] ARE PART OF
THIS.
SUPPORT TO REMIND EVERYONE WHEN
AT A PROGRAM IT IS NOT JUST
DOLLAR SUPPORT BUT THERE IS
ENORMOUS IN KIND RESOURCES WITH
PROFESSIONALS AND EXPERTS IN THE
SPACE DESIGNED TO HELP BOTH ON
TECHNOLOGY AND CLINICAL
APPLICATIONS AND CLINICAL TRIALS
AND MARKETS AND UNDERSTANDING
THOSE.
OF COURSE, THEN, COUPLING
STRONGLY INTO REGULATORY PATHWAY
THAT IS AN ULTIMATE GOAL AND YOU
WANT THESE THINGS TO GET OUT
INTO THE HANDS OF THE PUBLIC AS
QUICK AS POSSIBLE.
INTERESTING AND ASTOUNDING
STATISTIC EMERGING IN
NEURODISCUSSIONS IN WEEKLY
FUNDING PANEL MEETINGS IF YOU
HAVE USED -- HOW MANY HAVE USED
A COVID FLU MULTIPLEX TEST?
OKAY. ONLY HARDCORE.
100% OF TESTS ON MARKET AS OF
THIS DATE FROM THESE
MANUFACTURERS BOTH OVER THE
COUNTER AS WELL AS POINT OF CARE
HAVE GONE THROUGH THE RAD X
PROCESS AND CAPACITY FOR ALL OF
THESE TESTS IS UP TO 46 MILLION
TESTS PER WEEK AND A FEW OTHERS
ARE IN THE PIPELINE AND IT GETS
US UP TO 60 OR 65 MILLION PER
WEEK.
THIS IS AMAZING AND WE HAVE A
MOMENT IN TIME WITH BRAGGING
RIGHTS IN A SENSE FOR SUCH AN
IMPACTFUL I DON'T KNOW,
CONTRIBUTION TO TESTING AND
DIAGNOSTIC MARKET.
IT UNDERSCORES AMAZING WORK THAT
RAD X TEAMS ARE DOG AND THIS
WILL ULTIMATELY WE HOPE BECOME
MUCH MORE WIDELY DISSEMINATED IN
TEST TREAT PARADIGMS AND ONE
THING I DIDN'T MENTION IS THIS
IS FOR THIS FLU SEASON AND TESTS
HAVE BEEN AUTHORIZED IN PREVIOUS
FLU SEASONS AND THIS FLU SEASON
THIS IS 100% OF THE MULTIPLEX
TESTS.
IN THE SORT OF REOCCURRING
DISCUSSION THAT WE HAVE ABOUT IF
YOU TEST AND YOU ARE POSITIVE,
YOU WANT TO TREAT RIGHT AWAY AND
THIS PROGRAM TEST TO TREAT AND
TEFLT TO TREAT PILOT PROGRAM HAS
WRAPPED UP WITH ENORMOUS
SUCCESS.
WHAT IS REALLY INTERESTING, WE
HAD THESE TARGET IN 60,000.
WE HIT OVER 80,000.
WE HAD TELEHEALTH VISITS AND
AGAIN TARGETS BETWEEN 5 AND
6,000 AND 8600 TARGET VISITS
THAT WERE ACTUALLY ACHIEVED.
EXCEEDING ALL THE EXPECTED
PROJECTED GOALS AND TARGETS WITH
A REALLY INTERESTING SURGE THAT
TOOK PLACE IN APRIL AND ANDREW
HAS ANALYZED THIS DATA VERY
CAREFULLY AND ANDREW IF YOU CAN
STAND UP AND I DON'T KNOW IF
PEOPLE HAVE QUESTIONS THIS IS AN
AMAZING PROGRAM.
WE ARE TOTALLY OUT OF OUR SWIM
LANE HERE IN SOME SENSE AND
ANDREW AND COLLEAGUES HAVE BUILT
UP THIS PARTNERSHIP WITH
MULTIPLE FEDERAL AGENCIES THAT
ARE VERY INTERESTED IN DIFFERENT
FACETS OF PROBLEM.
FROM OUR PERSPECTIVE WE CHECKED
ALL OF THE BOXES ON TECHNICAL
FEASIBILITY AND KNOW THIS CAN BE
DONE AND CAN BE DONE WITH
NUCLEIC ACID TESTS THIS IS
LOSERA OVER THE COUNTER NUCLEIC
ACID TESTS AND ANDREW CAN YOU
HELP INTERPRET AT THE TOP HERE
IS A LITTLE NEWS STORY FROM
FORBES AND WILL TURN IT OVER TO
YOU TO TELL A LITTLE ABOUT THE
STO
STORY.
IT IS A NEW MEASURE OF SUCCESS.
>> THANK YOU, BRUCE.
YEAH. WE ALWAYS ADVERTIZED THIS
PROGRAM AS A PILOT.
MOSTLY REALLY DUE TO LIMITED
FUNDING AND HAD ALSO OUR
RESEARCH GOALS WE WANTED TO MEET
AT NIH AND PARTNERED WITH CDC
WHO OF COURSE HAD THE PUBLIC
HEALTH DRIVE FOR DOING THIS.
UPON REALLY MAKING A FORMAL
ANNOUNCEMENT THAT THE PROGRAM
WAS SHUTTING DOWN AND THERE WAS
AN ALMOST SUPPORT AND WE WERE
CONTACTED BY FORBES ABOUT WHY
WAS THIS HAPPENING AND THERE WAS
A LOT OF ORGANIZATIONS AND THERE
WAS ACTUALLY LOOKS LIKE A LETTER
BEING WRITTEN AND SUBMIT TODAY
NIH DIRECTOR ASKING TO KEEP
PROGRAM GOING THAT HAS 200
SIGNATURES AND 20 COMPANIES ON
BOARD.
YOU KNOW, THERE IS A NEED FOR
THESE TYPES OF PROGRAMS AND WE
ARE IN DISCUSSIONS WITH CDC AND
HAVING THEM MAYBE PICK THIS UP
AND CONTINUE WITH OTHER PROGRAMS
AND THIS CALENDAR YEAR THERE IS
STILL SOME OTHER SUBSIDIES IN
PLACE FOR UNINSURED INDIVIDUALS
AND SCOPE TO ACCESS SERVICES AND
END OF PUBLIC HEALTH EMERGENCY
AND THIS IS NOW SLOWLY GOING
AWAY AND NEED IS THERE AND
PEOPLE WANT IT AND IT WAS GREAT
TO SEE THAT INTEREST FROM THE
COMMUNITY OVER THE NEXT 6 MONTHS
IS WE COLLECTED DATA ANALYSIS
PROGRAM THAT ENDED A FEW WEEKS
AGO AND LOOK OUT IN THE NEXT FEW
MONTHS FOR FINDINGS BEING
PUBLISHED IN TRADITIONAL
ACADEMIC JOURNALS AND WE HAD A
GRASSROOTS WORK WITH THE
COMMUNITY FOR RECRUITING PEOPLE
IN THE PROGRAM AND WILL BE
DISSEMINATING FINDINGS THROUGH
THOSE KIND OF MORE GRASSROOTS
COMMUNITY CHANNELS.
>> THANK YOU ANDREW.
WHAT IS AMAZING TO ME IS WE ARE
VERY COMFORTABLE IN WORKING ON
TECHNICAL PROBLEMS AND WORKING
ON SYMPTOMS AND WILL HAVE A
DISCOVERY ABOUT SOMETHING THAT
IS REALLY INTERESTING AND TELL
FRIENDS AND MAYBE WILL STOP THAT
PROGRAM AND, YOU KNOW, A
COLLEAGUE MAYBE WILL SAY SAD TO
SEE YOU ENDED THAT RESEARCH
LINE.
IT IS NOT VERY -- NO ONE REALLY
CARES THAT MUCH.
YOU KNOW?
IT IS SO NARROW COMMUNITY AND
WHEN WE STEPPED OUT SORT OF INTO
THIS INTERSECTION BETWEEN A
STRONG PUBLIC HEALTH NEED AND
PROVIDING A SERVICE, THEN WE
REALLY SAW THIS RESPONSE WHERE
ARTICLES ARE COMING OUT AND
PEOPLE ARE VERY DISAPPOINTED
THAT WE ARE ENDING THIS PROGRAM
AND OUR GOAL WITH THE PROGRAM
WAS TO UNDERSTAND TECHNICAL GOAL
AND FEASIBILITY.
IT IS KIND OF OPENED MY EYES UP
TO DIFFERENT POTENTIAL IMPACTS
WE HAVE IN PUBLIC HEALTH.
>> THANKS, ANDREW.
>> SO SWITCHING TO THE TRAINING
AND DISSEMINATION TOPIC AND OF
COURSE YOU KNOW FOR THOSE OF YOU
WHO ARE SUPPORTING TRAINEES,
THIS IS A REALLY BIG, BIG ITEM
THAT HAS CUT ACROSS ALL OF NIH
AND ALL ACROSS THE FEDERAL
SPACE.
NRSA PAY LEVEL INCREASES AND HOW
YOU WILL MANAGE AND TRACK THAT
WITHIN YOUR GRANT PORTFOLIOS AND
IMPACT ON YOU AS AN INVESTIGATOR
I REALLY ENCOURAGE YOU TO GET IN
TOUCH WITH DANA AND TINA AND
DAVE TO THINK THROUGH THAT.
WE WILL SEE ANOTHER STAGE AND
CURRENTLY HAVE 4% AND 8
INCREASES IN PRE AND POST
DOCTORAL FELLOWS THAT ARE IN THE
CURRENT YEAR.
WE ARE GOING TO SEE MORE
INCREASES TO COME WITH THE
ADVISORY COUNCIL TO THE DIRECTOR
REALLY SUGGESTING AROUND A
$70,000 PAY LEVEL FOR POST
DOCTORAL FELLOWS AND IS A
TARGETED STRATEGY TO GET TO THAT
COMING FROM NIH.
THAT WILL HAPPEN OVER TIME.
AND JUST AS A REMINDER OF THE
ENORMITY OF THIS THERE IS 100 --
17 THOUSAND NSA SCHOLARS ACROSS
THE NIH AND 180 WITHIN NIBIB.
SO WE REISSUED THE ESTEEMED AND
TEAM-BASED DESIGN PROGRAMS.
THESE HAVE GROWN OVER THE LAST
SEVERAL YEARS AND WE ARE REALLY
PROUD OF THEM AND ESTEEMED
PROGRAM HAS 16 BOARDS INCLUDING
A NEW AWARD AT LOUISIANA STATE
UNIVERSITY AND RENEWAL OF UP SAN
ANTONIO PROGRAM AND TEAM BASED
DESIGN IS ANOTHER R25 AND ARE 19
PROGRAMS NOW WITH 4 PENDING
AWARDS.
SO PLEASE CONTACT TINA AND DAVE.
WE ARE REALLY HOPEFUL TO BE ABLE
TO CONTINUE TO GROW THIS NETWORK
AND THINK IT PLAYS A VERY, VERY
IMPORTANT ROLE IN EXPANDING OUR
COMMUNITY AND PIPELINE AND
OPPORTUNITIES FOR OUR
INVESTIGATORS.
RELATED TO THAT AND WE TALKED
ABOUT THIS A LITTLE WITH DR.
CLAYTON BEING HERE IS KIND OF
OUR CORE CURRICULUM IN A SENSE.
THERE IS THE DESIGN PROJECTS
THAT STUDENTS ARE ALL ENGAGED IN
AND ANNOUNCING THIS AGAIN AND
REMINDING EVERYONE OF THE MAY
31ST SUBMISSION DATE WE HOPE TO
SEE LOTS OF APPLICATIONS AND
160,$160,000 IN PRIZES THIS YEAD
MANY INSTITUTES ARE PART OF
THIS.
THERE IS $120,000 FIRST PRICE
AND $815,000 PRIZES AND WORKING
THE IMAGINE OUT STUDENTS HAVE
PRETTY GOOD ODDS TO GET ONE OF
THESE AWARDS AND THERE IS A
$10,
$100,005,000 PRIZE AND $15,000
HONORABLE PRIZE AND FAIR AMOUNT
OF MONEY GOING DIRECTLY INTO
BANK ACCOUNT OF STUDENTS AND
THEY SHOULD BE EXCITED ABOUT
THAT.
THERE IS ENORMOUS SUCCESS WITH
STUDENTS THAT I WILL PULL OUT
THIS 20202 DEBUT CHALLENGE
AWARDEE SUPPORTED BY NCI AND WAS
THEIR TOP AWARD AND $15,000
AWARD FROM NATIONAL CANS
INSTITUTE FROM TECHNO WILLING TO
STABILIZE SKULL AND NEUROSURGERY
PARTICULARLY NEUROSURGERY FOR
TUMORS AAND THAT COMPANY WAS
LAUNCHED AND WENT THROUGH C3I
BOOT CAMP AND CHALLENGE AND HERE
WE HAVE ACTUALLY ALL STUCK WITH
IT.
THEY -- IN MED SCHOOL AND GRAD
SCHOOL. HERE IS ALLIE THEY
RENAMED COMPANY XANDER MEDICAL
IS RENAMED AND SHE IS A GRADUATE
AT NORTHEASTERN WORKING ON
ADVANCING AND DEVELOPING AND
COMMERCIALIZING THIS TECHNOLOGY
WITH UPDATED PROTOTYPES AND AS
YOU KNOW STUDENTS GET HOOKED ON
THESE THINGS AT EARLY STAGES IN
THEIR CAREER AND ARE LESSONS
THEY LEARN AND CONTINUE TO WORK
ON AS THEY PROGRESS IN WHATEVER
TRAINING OPPORTUNITY THAT THEY
ARE PURSUING.
WE HAVE A NEW CONFERENCE AWARD
PROGRAM LAUNCHED BY ALBERT
AVILLA AND ARE HOPING TO MAKE
SOMEWHERE BETWEEN 20 AND 40
AWARDS PER YEAR AND IT IS NOT AN
ENORMOUS AMOUNT OF MONEY FOR
EACH STUDENT AND IT IS WHAT WE
CAN AFFORD AND IS REASONABLE FOR
CONFERENCES THAT IS UP TO $1500
IN SUPPORT.
IDEA IS TO GET STUDENTS TO
CONFERENCES AND WE HAVE SORT OF
SUGGESTED FOUR MAJOR ONES OVER
COURSE OF YEAR AND BMES MEETING
AND PLATONICS WEST AND MEDICAL
IMAGING MEETING AND SOCIETY
PROVIDING MATERIALS AND ARE NOT
CONSTRAINING IT TO THESE.
WE SUGGESTED THESE BECAUSE THESE
ARE WHERE NIBIB PROGRAM FOLKS GO
AND GOAL IS NOT JUST TO GET
STUDENTS TO CONFERENCES TO SEE
SCIENTIFIC CONTENT AND ENGAGED.
THAT IS PART OF IT AND IT IS TO
MEET WITH NIBIB PROGRAM FOLKS
AND PARTICIPANTS AT THAT
CONFERENCE AND GET EXCLUSIVE
ATTENTION ABOUT WHERE CAN I GO
AND WHERE ARE OPPORTUNITIES AND
HOW DO YOU GET FUNDING AT
DIFFERENT STAGES IN YOUR CAREER
TO BEGIN THAT DIALOGUE AND THIS
IS DESIGNED TO BE STIMULATORY TO
OUR COMMUNITY TO HELP, AGAIN,
ACCELERATE THAT PIPELINE AND ARE
INTERESTED IN YOUR THOUGHTS ON
THAT AND HOPEFULLY YOU WILL
NOMINATE AND POINT THIS OUT TO
VARIOUS STUDENTS.
WE ARE EXCITED TO GET THIS
PROGRAM LAUNCHED.
BIOMEDICAL ENGINEERING SUMMER
INTERN SHL PROGRAM AND MANU
REALLY EXPANDED SCOPE OF THIS
AND IS EXCITING AND FRUSTRATING
IN WAY TO SEE MORE THAN 200
APPLICATIONS WERE RECEIVED AND
THANKS TO YOU AND OUR COMMUNITY
FOR GETTING WORD OUT AND WE ARE
EXPANDING BEYOND BIOMEDICAL
ENGINEERING STUDENTS GOING INTO
MANY DIFFERENT AREAS.
THERE IS 2 24 INTERNS THAT HAVE
BEEN SELECTED THAT IS UP 16 FROM
LAST YEAR AND WOULD LIKE THAT
ACCEPTANCE RATE UP HIGHER IF WE
CAN.
WE ARE COMMITTED TO THAT.
WE ARE CERTAINLY HAPPY TO GO
AROUND TO OTHER INSTITUTES AND
CENTERS AND SEE IF THEY CAN
CONTRIBUTE TO THE SUPPORT AND,
AGAIN, AS I MENTIONED
ELIGIBILITY IS OPEN TO ALL
UNDERGRADUATE STUDENTS AND BME
AND STEM MAJORS AND
REPRESENTATION FROM 21 DIFFERENT
COLLEGES AND UNIVERSITIES AND
THIS IS REALLY EXCITING AND SO
IT IS STARTING AT THE BEGINNING
OF JUNE.
ANOTHER PROGRAM THAT WE HAVE
BEEN TALKING ABOUT AND THATMONA
HAS BEEN INSTRUMENTAL IN GETTING
THIS LAUNCHED IS SO HAS ANNE AND
EXECUTIVE OFFICER AND WHOLE
ADMINISTRATIVE MANAGEMENT TEAM.
THIS IS A COMPLEX MOVE AND SOME
KNOW THAT NSF HAS GRADUATE
INTERN PROGRAMS AND IF YOU ARE
AN NSF SUPPORTED GRADUATE
STUDENT ON A PI'S GRANT OR IF
YOU HAVE OWN GRADUATE RESEARCH
FELLOWSHIP YOU CAN DO AN
INTERNSHIP FOR 6 MONTHS PAID AT
NATIONAL LABS AROUND THE
COUNTRY.
OKAY. WE ARE A NATIONAL LAB
HERE AT NIH.
SO, WE THOUGHT THAT WE NEEDED TO
REALLY KIND OF GET ENGAGED IN
THIS.
OF COURSE SUSAN OUR CLOSE
COLLEAGUE HEAD OF NSF
ENGINEERING DIRECTOR WORKED WITH
US TO MAKE THIS HAPPEN.
OVER THE NEXT COUPLE OF YEARS,
WE WILL PARTNER WITH THEM AND
HOPE TO FUND ANYWHERE BETWEEN 8
AND 10 INTERNSHIPS OVER THIS
PERIOD OF TIME.
AS YOU HAVE PROBABLY HEARD
ALREADY FROM MANU, YOU KNOW, HE
HAS GONE AROUND AND ORGANIZED
THESE EVENTS AND TRIED TO
UNDERSTAND WHAT PEOPLE ARE
LOOKING FOR IN THE IRP AND MANU,
I DON'T WANT TO -- YOU SHOULD
TELL.
WHAT ARE PEOPLE LOOKING FOR.
>> [INDISCERNIBLE].
>> LOOKING FOR EVERYTHING.
GREAT ANSWER. IF YOU CAN
IMAGINE GREAT SPONSOR FROM DATA
CENTER AND LOOKING FOR PEOPLE
DOING IMAGE ANALYSIS AND
PROCESSING AND AI AND MACHINE
LEARNING AND LOOKING FOR PEOPLE
DOING SOFT BIOMATERIALS AND
CENSUS AND GREAT MRI PEOPLE ON
KAN ZAGS SDAS AND PROCESSING
IMAGES LOOKING FOR EVERYTHING.
AGAIN, ALL THINGS WE DO THEN
THAT IS WHAT IR INVESTIGATORS
ARE LOOKING FOR AND SEND
STUDENTS WE HAVE SEEN NUMBER
INQUIRIES ALREADY AND THIS IS AN
EXCITING LAUNCH THAT WE ARE
TRYING TO MANAGE.
>> THANK YOU MANU.
I MEAN, THAT -- I THINK THAT
REALLY UNDERSCORES KIND OF WHAT
WE HAVE ALL FELT VERY STRONGLY
AND WE THINK THIS IS A KIND OF A
FAST TRACK TO BEING ABLE TO HELP
CHANGE THE CULTURE A LITTLE BIT
WITHIN THE IRP PROGRAM TO BRING
IN A BUNCH OF ENGINEERING AND
PHYSICAL SCIENCE STUDENTS INTO
OUR UNIVERSE YEAR AND HELP WITH
ACCELERATING TRAINING AND
BIOMEDICAL PROBLEMS IN A UNIQUE
ENVIRONMENT WITH CLINICAL CENTER
AND COLLABORATIVE OPPORTUNITIES
AND ARE PRETTY GOOD AWARDS AND
IS UP TO $55,000 PER STUDENT OR
6 MONTH FELLOWSHIP PERIOD.
AGAIN, IT IS STRUCTURED EXACTLY
LIKE THE NSF INTERNSHIP PROGRAM
THAT YOU HAVE SEEN IF YOU GO TO
THE NSF WEBSITE.
WE HAVE A PIECE OF THAT WEB SITE
WITH THIS DEAR COLLEAGUE LETTER
THAT IS EXCITING TO SEE.
RELATED, AGAIN, TO SORT OF THE
COMMUNITY BUILDING AND SO MANU
AND TEAM ARE -- THEY HAVE COME
UP WITH AN IDEA TO HAVE A
SATELLITE MEETING TO BME
CONFERENCE DAY BEFORE BMES
CONFERENCE AND THIS IS REALLY
ABOUT KIND OF A BROAD TOPIC OF
HOW DO WE BUILD BRIDGES ACROSS
NIH AND BROADER ENGINEERING AND
TECHNOLOGY DEVELOPMENT
COMMUNITY.
SO, WE ARE HOPING TO INCLUDE OUR
INTRAMURAL INVESTIGATORS AND
NEEDS AND THINGS THAT MANU JUST
ARTICULATED AND ADVERTISE SOME
PROGRAMS AND BUILD COMMUNITY AND
GET PEOPLE TALKING AND HELP TO
ENCOURAGE AND DRIVE
COLLABORATIONS AND WE CAN SEE
NEW PROGRAMS AND OPPORTUNITIES
AND I'M PRETTY SURE THAT WE
DON'T HAVE THE FINAL
CONFIRMATION FROM DR. BER TAN
OELI'S OFFICE YET.
SHE HAS IT ON HER CALENDAR AND I
EXPECT SHE WILL BE ABLE TO COME
TO THAT EVENT THAT DAY AND
TALKING ABOUT A VARIETY OF
DIFFERENT OTHER EVENTS THAT WILL
BE HELD WITH INTERESTING
SPEAKERS AND ENGAGEMENT AND
PARTICIPATION AND ARE LOOKING
FORWARD TO YOUR FEEDBACK ON THAT
AS WELL.
SO IF YOU ARE FAMILIAR WITH
SPEAKING OF AI AND WE ACTUALLY I
THINK IT IS A MANDATORY
REQUIREMENT THAT LIKE SOME
FRACTION OF OUR SLIDE PATH TO
COVER AI AND MACHINE LEARNING
AND COMPUTATION AND MODELING AND
SO FORTH.
BRIDGE TO AI PROGRAM AND I SEE
THAT GRACE IS HERE WHO WAS
LEADING OUR EFFORTS ON THIS.
GRACE I WILL ASK YOU A HARD
QUESTION IN A MINUTE.
JUST RECENTLY HAVE HAD THEIR
FIRST MEETING OPEN HOUSE WITH
OVER 100 PEOPLE PUBLIC
PARTICIPATION COVERING ALL OF
THE KINDS OF APPROACHES TO AI
COLLABORATIVE APPROACHES AND
ETHICAL CONSIDERATIONS THAT IS A
HUGE FOUNDATIONAL ELEMENT OF
BRIDGE TO AI.
THERE ARE VERY BEAUTIFUL DATA
SETS THAT COVER A WIDE VARIETY
OF TOPICS AND GRACE IF YOU CAN
SORT OF COVER WHAT THOSE DATA
SETS ARE.
IF YOU CAN SCAN THE Q.R. CODE, I
WILL ALSO ADVERTIZE A REALLY
KIND OF -- WE LIKE WEIRD AND
OBSCURE THINGS AND IF YOU LOOK
AT THE BRIDGE TO AI WEBSITE
THERE IS A THEME SONG ON THERE
AS WELL WHICH IS A NERDY CHEESY
THEME SONG THAT I THINK YOU WILL
ALL APPRECIATE IT.
IS THAT THEME SONG HUMAN
GENERATED OR AI GENERATED OR
COLLABORATION BETWEEN THEM?
>> I BELIEVE A COLLABORATION
BETWEEN THE TWO AND ACTUALLY A
PRETTY STRONG COMPETITION OF
MULTIPLE THEME SONG SUBMISSIONS.
>> ALL RIGHT. NOW THAT I
CONFUSED EVERYONE WITH IT WE
DON'T WANT TO HEAR THEME SONGS
BLARING ON PHONES NOW BUT AT
NEXT. GRACE IF YOU CAN
SUMMARIZE DATA SETS ARE
EXTRAORDI
EXTRAORDINARY.
>> I ENCOURAGE ALL OF YOU THANK
YOU FOR TIME TO GO TO OPEN HOUSE
RECORDING AND BRIDGE TO AI
PROGRAM IS REALLY FOCUSED ON
AREA OF THINKING ABOUT ETHICAL
CREATING A CULTURE OF ETHICS
INQUIRY THROUGHOUT ENTIRE DATA
PREPARATION PROCESS AND NOT JUST
COMPLIANCE AND YOU WILL HEAR A
LOT OF LEGAL EXPERTS TALKING AS
WELL AS ANTHROPOLOGISTS AND
PHILOSOPHERS TALKING ABOUT
ISSUES THEY ARE DEALING WITH IN
TERMS OF RELEASE AND IS FIRST
PUBLIC RELEASE OF DATA AND UP TO
RELEASE THERE WAS A HUGE
DISCUSSION BETWEEN ETHICS AND
DATA SCIENCE FOLKS IN TERMS HOW
THEY WOULD RELEASE DATA AND
CONSENT OPEN HOUSE PARTICIPANTS
TO ACTUALLY USE DATA IN AN
ETHICAL WAY YOU WILL SEE HOW
THEY PREPARE THIS DATA FOR THIS
RELEASE SO GRAND CHALLENGE THAT
THIS IS ELUDING TO WE HAVE 4
CHALLENGES AND ONE IS FOR VOICE
MOST OF THEM AND WE HAVE
FUNCTIONAL GENOMICS DATA AND NOT
HUMAN DATA AND LAST ONE IS
[INDISCERNIBLE] GRAND CHALLENGE
THAT IS IDEA OF LOOKING AT HOW
ONE GOES FROM A HEALTHY STATE OR
GOING FROM DISEASE BACKED STATE
TO HEALTHY STATE